

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
10 December 2009 (10.12.2009)

(10) International Publication Number  
WO 2009/146523 A1

(51) International Patent Classification:

*A61K 39/00* (2006.01) *A61P 25/28* (2006.01)  
*A61K 39/39* (2006.01) *A61P 35/00* (2006.01)  
*A61K 9/127* (2006.01) *A61P 37/04* (2006.01)

[CA/CA]; 17 Birchwood Terrace, Dartmouth, Nova Scotia B3A 3W2 (CA).

(21) International Application Number:

PCT/CA2009/000692

(22) International Filing Date:

22 May 2009 (22.05.2009)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/059,043 5 June 2008 (05.06.2008) US

(71) Applicant (for all designated States except US): **IMMUNOVACCINE TECHNOLOGIES INC.** [CA/CA]; 1819 Granville Street, Suite 303, Halifax, Nova Scotia B3J 3R1 (CA).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **MANSOUR, Marc** [CA/CA]; 17 Alton Drive, Halifax, Nova Scotia B3N 1L8 (CA). **SAMMATUR, Leeladhar** [CA/CA]; 21 Parkland Drive, Apt. 317, Halifax, Nova Scotia B3S 1R8 (CA). **MACDONALD, Lisa Diana** [CA/CA]; 5385 Duffus Street, Halifax, Nova Scotia B3K 2L9 (CA). **KARKADA, Mohan** [CA/CA]; 19 Loppie Close, Beechville, Nova Scotia B3T 2G4 (CA). **WEIR, Genevieve Mary** [CA/CA]; 468 Spring Avenue, Dartmouth, Nova Scotia B2W 1X8 (CA). **FUENTES-ORTEGA, Antar**

(74) Agent: **SMART & BIGGAR**; P.O. Box 2999, Station D, 900-55 Metcalfe Street, Ottawa, Ontario K1P 5Y6 (CA).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) Title: COMPOSITIONS COMPRISING LIPOSOMES, AN ANTIGEN, A POLYNUCLEOTIDE AND A CARRIER COMPRISING A CONTINUOUS PHASE OF A HYDROPHOBIC SUBSTANCE




FIG. 1

(57) Abstract: The invention provides a composition comprising: an antigen; liposomes; a polyI:C polynucleotide; and a carrier comprising a continuous phase of a hydrophobic substance. Methods for making and using the compositions are also provided.

**COMPOSITIONS COMPRISING LIPOSOMES, AN ANTIGEN, A POLYNUCLEOTIDE  
AND A CARRIER COMPRISING A CONTINUOUS PHASE OF A HYDROPHOBIC  
SUBSTANCE**

**CROSS-REFERENCE TO RELATED APPLICATIONS**

5 This application claims the benefit of and priority from United States Provisional Patent Application No. 61/059,043, filed June 5, 2008.

**FIELD OF THE INVENTION**

The present application relates compositions comprising liposomes, an antigen, a polyI:C polynucleotide and a carrier comprising a continuous phase of a hydrophobic substance, and their use.

**BACKGROUND OF THE INVENTION**

Conventional vaccines may comprise an antigen, an adjuvant and a pharmaceutically acceptable carrier. It is known that a polyI:C polynucleotide may be useful as an adjuvant. It is also known that liposomes may be useful in vaccine compositions (see Applicants' issued US patent 6,793,923). However, to Applicants' knowledge, the art does not teach or suggest combining an antigen, a polyI:C polynucleotide, liposomes and a hydrophobic carrier in a vaccine composition.

**SUMMARY OF THE INVENTION**

Applicants have now discovered that a composition comprising an antigen, a polyI:C polynucleotide, liposomes and a carrier comprising a continuous phase of a hydrophobic substance may provide surprisingly higher antibody titers and a higher percentage of activated or memory CD8+ T cells than either conventional vaccine compositions containing polyI:C polynucleotides in an aqueous carrier, or compositions comprising liposomes, a hydrophobic carrier and an alum adjuvant.

Accordingly, in one aspect, the invention provides a composition comprising: (a) an antigen; (b) liposomes; (c) a polyI:C polynucleotide; and (d) a carrier comprising a continuous phase of a hydrophobic substance.

In another aspect, the invention provides a method for making a composition, said method comprising combining, in any order: (a) an antigen; (b) liposomes; (c) a polyI:C polynucleotide; and (d) a carrier comprising a continuous phase

of a hydrophobic substance. In an embodiment, the antigen is encapsulated in the liposomes. In an embodiment, the polyI:C polynucleotide is encapsulated in the liposomes.

In another aspect, the invention provides a composition prepared

5 according to the methods described above.

In another aspect, the invention provides a method comprising administering a composition as described above to a subject. In an embodiment, the method is a method for inducing an antibody response or cell-mediated immune response to the antigen in the subject.

10 Other aspects and features of the present invention will become apparent to those of ordinary skill in the art upon review of the following description of specific embodiments of the invention in conjunction with the accompanying figures.

#### BRIEF DESCRIPTION OF THE FIGURES

In the figures, which illustrate embodiments of the invention by way of

15 example only:

**Figure 1** is a graph showing the results of vaccination of three groups of mice (n=9 or 10) as follows: Group 1 mice were vaccinated with 1 microgram rHA and 4 micrograms polyI:C in a 30 microliter dose formulated as a liposome/ polyI:C/ hydrophobic carrier vaccine (Vaccine B, the invention). Group 2 mice were treated with 20 Vaccine A comprising 1 microgram rHA and 60 micrograms alum in a 30 microliter dose of liposome/ alum/ hydrophobic carrier formulation. Group 3 mice were vaccinated with 1 microgram rHA and 60 micrograms alum per 30 microliter dose of control alum vaccine. Humoral immune responses were measured by ELISA as described herein. For each 25 treatment group, the log10 values of the endpoint antibody titers were averaged and standard deviations calculated for each time point. P values were calculated using the student T test.

**Figure 2** is a graph showing the results of vaccination of two groups of mice (n=9 or 10) as follows: Group 1 mice were vaccinated with 1 microgram rHA and 4 micrograms polyI:C in a 30 microliter dose formulated as a liposome/ polyI:C/ hydrophobic carrier vaccine (Vaccine B, the invention). Group 2 mice were treated with 30 1 microgram rHA and 4 micrograms polyI:C per 30 microliter dose of control polyI:C

vaccine. Humoral immune responses were measured by ELISA as described herein. For each treatment group, the log10 values of the endpoint antibody titers were averaged and standard deviations calculated for each time point. P values were calculated using the student T test.

5                   **Figure 3** is a graph showing the results of vaccination of two groups of mice (n=8 or 9) as follows: Group 1 mice were vaccinated with a single dose of 1 microgram rHA and 10 micrograms polyI:C in a 50 microliter dose formulated as a lyophilized liposome/ polyI:C/ hydrophobic carrier vaccine (Vaccine C, the invention). Group 2 mice were treated with 1 microgram rHA and 100 micrograms alum per 50 10 microliter dose of control alum vaccine; mice were boosted 21 days post-vaccination. Humoral immune responses were measured by ELISA as described herein. For each treatment group, the log10 values of the endpoint antibody titers were averaged and standard deviations calculated for each time point.

15                   **Figure 4.** Enhanced anti-rHA antibody responses following vaccination with rHA antigen formulated in a liposome/ polyI:C/ oil carrier vaccine. Two groups of mice (n=9 or 10) were vaccinated as follows: Group 1 mice were vaccinated with 1 microgram rHA and 4 micrograms polyI:C in a 30 microliter dose formulated as a liposome/ polyI:C/ hydrophobic carrier vaccine (Vaccine B, the invention). Group 2 mice were treated with Vaccine A, 1 microgram rHA and 60 micrograms alum in a 30 microliter 20 dose of liposome/ alum/ hydrophobic carrier formulation. Humoral immune responses were measured by ELISA as described herein. For each treatment group, the log10 values of the endpoint antibody titers were averaged and standard deviations calculated for each time point. P values were calculated using the student T test.

25                   **Figure 5.** Enhanced anti-rHA antibody responses following vaccination with rHA antigen formulated in a liposome/ polyI:C/ oil carrier vaccine. Two groups of mice (n=9 or 10) were vaccinated as follows: Group 1 mice were vaccinated with 1 microgram rHA and 4 micrograms polyI:C in a 30 microliter dose formulated as a liposome/ polyI:C/ hydrophobic carrier vaccine (Vaccine B, the invention). Group 2 mice were treated with 1 microgram rHA and 4 micrograms polyI:C per 30 microliter dose of 30 control polyI:C vaccine. Humoral immune responses were measured by ELISA as described herein. For each treatment group, the log10 values of the endpoint antibody titers were averaged and standard deviations calculated for each time point. P values were calculated using the student T test.

**Figure 6.** Enhanced anti-rHA antibody responses following vaccination with rHA antigen formulated in a lyophilized liposome/ polyI:C/ oil carrier vaccine. Two groups of mice (n=9 or 10) were immunized as follows: Group 1 mice were vaccinated with a single dose of 1.5 micrograms rHA and 12.5 micrograms polyI:C in a 50 microliter dose formulated as a lyophilized liposome/ polyI:C/ hydrophobic carrier vaccine (Vaccine D, the invention). Group 2 mice were treated with 1.5 micrograms rHA and 100 micrograms alum per 50 microliter dose of control alum vaccine; mice were boosted 28 days (week 4) post-vaccination. Humoral immune responses were measured by ELISA as described herein. For each treatment group, the log10 values of the endpoint antibody titers were averaged and standard deviations calculated for each time point. P values were calculated using the Student T test.

**Figure 7.** Number of antigen-specific CD8 cells within a CD8-positive T cell population following vaccination. Three groups of BALB/c mice (n=4) were vaccinated as follows: Group 1 mice were vaccinated with 1.5 micrograms of rHA and 12.5 micrograms of RNA-based polyI:C adjuvant in a 50 microliter dose formulated as lyophilized liposome/ polyI:C/ hydrophobic carrier vaccine (Vaccine D, invention) intramuscularly. Group 2 mice were vaccinated with 50 microliters of Vaccine D subcutaneously. Group 3 mice were vaccinated with 1.5 micrograms of rHA and 100 micrograms of Imject Alum adjuvant in 50 microliters of 50 millimolar phosphate buffer (pH 7.0) intramuscularly. All vaccines were given once without boosting. Antigen-specific CD8+ T cells were detected twenty-two days after vaccination in the splenocytes of animals using tri-colour flow cytometric analysis. Cells were stained with anti-CD8β-APC, anti-CD19-FITC and a PE-pentamer specific for H2-Dd bearing the immunodominant epitope of rHA, I9L. Results are expressed as average percentage of pentamer positive cells in a population of CD8β-positive/ CD19-negative cell population, +/- standard deviation. The background staining detected in the splenocytes isolated from naïve cells was subtracted. \*p=<0.025, \*\*p=<0.005, as compared to Group 3.

**Figure 8.** Hemagglutination inhibition (HAI) titers following a single vaccination against rHA formulated in the invention. One group of mice and one group of rabbits (n=5) were vaccinated as follows: The group of mice were vaccinated with 0.5 micrograms rHA and 12 micrograms polyI:C in a 50 microliter dose formulated as a lyophilized liposome/ polyI:C/ hydrophobic carrier vaccine (Vaccine E, the invention). The group of rabbits were treated with Vaccine F (the invention), 2 microgram rHA and 50 micrograms polyI:C in a 200 microliter dose of lyophilized liposome/ polyI:C/ hydrophobic carrier formulation. Humoral immune responses were measured by hemagglutination

inhibition assay, as described herein; before vaccination (pre-vaccination) and at 4 (rabbits) or 5 (mice) weeks afterwards. For each animal group, the log10 values of the HAI titers were averaged and standard deviation calculated.

**Figure 9.** Enhanced anti- $\beta$ -amyloid antibody responses following

5 vaccination with a mixture of  $\beta$ -amyloid and F21E peptides formulated in a liposome/polyI:C/ oil carrier vaccine. Two groups of mice (n=9) were vaccinated as follows: Group 1 mice were vaccinated with 10 micrograms  $\beta$ -amyloid, 20 micrograms F21E and 200 micrograms alum in a 100 microliter dose formulated as a liposome/ alum/hydrophobic carrier vaccine (Vaccine G). Group 2 mice were treated with 10 micrograms  
10  $\beta$ -amyloid, 20 micrograms F21E and 10 micrograms polyI:C per 100 microliter dose formulated as liposome/ polyI:C/ hydrophobic carrier (Vaccine H, the invention). Humoral immune responses were measured by ELISA as described herein. For each treatment group, the log10 values of the endpoint antibody titers were averaged and standard deviation calculated for each time point. P values were calculated using the student T  
15 test.

**Figure 10.** Vaccines formulated in a liposome/polyI:C/ hydrophobic carrier

formulation are capable of raising cellular and humoral immune responses. Two groups of mice (n=5) were vaccinated as follows: Group 1 mice were vaccinated with 0.5 micrograms rHA and 12 micrograms polyI:C in a 50 microliter dose formulated as a  
20 lyophilized liposome/ polyI:C (high)/ hydrophobic carrier vaccine (Vaccine E, the invention). Group 2 mice were treated with 0.5 micrograms rHA and 2.5 micrograms polyI:C per 50 microliter dose formulated as lyophilized liposome/ polyI:C (low)/ hydrophobic carrier (Vaccine I, the invention). Indicators of humoral (IgG1) and cellular (IgG2A) immune responses were measured by ELISA as described herein. For each  
25 treatment group, the log10 values of the endpoint antibody titers were averaged and standard deviations calculated for each time point.

**Figure 11** is a graph showing the average tumor volume of C57BL/6 mice

implanted with HPV16 E7 expressing C3 cells and vaccinated eight days later as follows: Group 1 mice were vaccinated with 100 microliters containing 15 micrograms of FP  
30 antigen and 150 micrograms of RNA-based polyI:C formulated in an emulsion with hydrophobic carrier (Control Emulsion vaccine). Group 2 mice were vaccinated with 100 microliters containing 15 micrograms of FP antigen and 150 micrograms of polyI:C formulated in liposome/ PolyI:C/ hydrophobic carrier (Vaccine K, invention). Group 3 mice received 100 microliters of PBS only. All groups contained eight mice. Tumor size

was measured once a week for five weeks after implantation. **Figure 11** shows the average tumor volume calculated for each group +/- SEM. P values were calculated for Group 1 and Group 2 using Students' T test, \*p=<0.1, \*\*p=<0.05.

**Figure 12** is a graph showing the average tumor volume of C57BL/6 mice implanted with HPV16 E7 expressing C3 cells and vaccinated five days later as follows: Group 1 mice received 100 microliters containing 10 micrograms of FP antigen and 20 micrograms of DNA based polyI:C formulated in liposome/ PolyI:C/ hydrophobic carrier (Vaccine L, invention). Group 2 mice received 50 microliters containing 10 micrograms of FP antigen and 20 micrograms of DNA based polyI:C formulated in lyophilized liposome/ 10 PolyI:C/ hydrophobic carrier (Vaccine M, invention). Group 3 mice received 50 microliters containing 10 micrograms of FP antigen formulated in lyophilized liposome/ hydrophobic carrier (Adjuvant control). Group 4 mice received 100 microliters of PBS only. All groups contained ten (10) mice. Tumor size was measured once a week for five weeks after implantation. **Figure 12** shows the average tumor volume calculated for each group +/- SEM. P values were calculated for Group 2 and Group 3 using Students' T test, \*p=<0.05.

**Figure 13.** Enhanced anti-rHA cellular response following vaccination with rHA antigen formulated in a lyophilized liposome/ polyI:C/ oil carrier vaccine. Two groups of mice (n=9 or 10) were immunized as follows: Group 1 mice were vaccinated with a 20 single dose of 1.5 micrograms rHA and 12.5 micrograms polyI:C in a 50 microliter dose formulated as a lyophilized liposome/ polyI:C/ hydrophobic carrier vaccine (Vaccine D, the invention). Group 2 mice were treated with 1.5 micrograms rHA and 100 micrograms alum per 50 microliter dose of control alum vaccine; mice were boosted 28 days (week 4) post-vaccination. Antigen specific cellular responses were measured by pentamer staining of CD8+ T cells specific for the H2-Kd epitope IYSTVASSL and flow cytometry. 25 Mice vaccinated with the invention as described generated an antigen-specific long-lasting cellular response. P values were calculated using the Student T test.

## DETAILED DESCRIPTION

The present application relates to compositions comprising liposomes, an 30 antigen, a polyI:C polynucleotide and a carrier comprising a continuous phase of a hydrophobic substance and their use.

Compositions of the invention, combining an antigen, a polyI:C polynucleotide, liposomes and a carrier comprising a continuous phase of a hydrophobic

substance provided surprisingly higher antibody titers than either conventional vaccine compositions containing polyI:C polynucleotides in an aqueous carrier, or compositions comprising liposomes, a hydrophobic carrier and an alum adjuvant.

The data described in Examples 1 and 2 herein are summarized in

5 **Table 1:**

**Table 1.**

	Composition	antibody titer (log10)	antibody titer (non-logged)
(1)	rHA antigen alum adjuvant liposomes hydrophobic carrier	5.41	256,000
(2)	rHA antigen polyI:C PBS carrier	6.01	1,024,000
(3)	rHA antigen polyI:C liposomes hydrophobic carrier	6.91	8,192,000

rHA = recombinant H5N1 influenza hemagglutinin glycoprotein

PBS = phosphate buffered saline carrier

10 It will be seen from the above table (**Table 1**) that the compositions of the invention (3) provided antibody titers that were more than the additive effect of either the combination of liposomes plus hydrophobic carrier (1), or the use of polyI:C (2). The additive effect of (1) and (2) would be a non-logged antibody titer of  $256,000 + 1,024,000 = 1,280,000$ . Instead, replacing the alum adjuvant in (3) with polyI:C gave an  
15 unexpectedly high non-logged antibody titer of 8,192,000, 6.4 times the expected additive effect. Furthermore, the antibody response generated with composition (3) was long lasting and the effect observed at the earlier time point (week 4 post-vaccination) described above was maintained at week 16 post-vaccination (Examples 4 and 5). The data described in Examples 4 and 5 herein are summarized in **Table 2**:

**Table 2.**

	<b>Composition</b>	<b>Average antibody titer (log10)</b>	<b>Average antibody titer (non-logged)</b>
<b>(1)</b>	rHA antigen alum adjuvant liposomes hydrophobic carrier	5.11	128,824
<b>(2)</b>	rHA antigen polyI:C PBS carrier	5.23	169,824
<b>(3)</b>	rHA antigen polyI:C liposomes hydrophobic carrier	6.21	1,621,810

The additive effect of (1) and (2) would be a non-logged average antibody titer of  $128,824 + 169,824 = 298,648$ . Instead, replacing the alum adjuvant in (3) with 5 polyI:C gave an unexpectedly high non-logged average antibody titer of 1,612,810, 5.4 times the expected additive effect.

The results observed with composition (3) described above were duplicated in a separate study that used a composition consisting of antigen (rHA), polyI:C, lyophilized liposomes, and a hydrophobic carrier and described in Example 3. 10 The average antibody titer observed with this composition at week 8 post vaccination was 2,884,031 (non logged) compared to 147,910 (non-logged) average titer observed with a standard alum-adjuvanted vaccine delivered twice to enhance its activity. This 19.4 fold average increase in titer was observed with one immunization of the composition described.

15 Vaccine compositions containing polyI:C, liposomes, and a hydrophobic carrier have the potential to generate antibody responses and/or cellular responses against a broad range of antigens. Examples 1 through 6 and Examples 8 and 9 demonstrate the ability to raise a significantly higher antibody response when combining all components of the composition against a recombinant protein (rHA) or a short peptide 20 ( $\beta$ -amyloid). These surprisingly high antibody titers were not observed without the use of a polyI:C polynucleotide specifically in the vaccine composition (Examples 1, 4, and 9), nor were they observed in the absence of liposomes and a hydrophobic carrier despite the use of polyI:C alone with an antigen (Examples 2 and 5). Similarly, the combination of all components of the composition generated a significantly more efficacious and longer- 25 lasting cellular immune response as illustrated in Example 7 and Examples 11 through 13

against a recombinant protein or a short peptide containing a known CTL epitope. Significant antigen-specific immune responses were detected when immunizing with the composition by at least two immunization routes (Example 7). The unusual efficacy in controlling tumor growth with the described invention were not observed without the use 5 of a polyI:C polynucleotide specifically in the composition (Example 12) and were not observed without the use of liposomes and despite the use of a polyI:C polynucleotide and a hydrophobic carrier with the antigen (Example 11). The ability to raise robust and long lasting humoral and cellular responses simultaneously with at least one immunization using all components of the described composition (Examples 6, 7, 10, and 13) illustrates 10 the particular usefulness of the composition in a wide range of medical applications including infectious diseases and cancers.

It is clear from the collection of examples described herein that vaccine compositions consisting of an antigen, liposomes, a hydrophobic carrier and ribo-or deoxyribo- polynucleotides containing inosine and cytosine residues in more than one 15 chemical configuration are capable of inducing unusually strong immune responses. The examples also describe more than one method to make the desired composition.

#### Antigens

The compositions of the invention comprise one or more antigens. As used herein, the term "antigen" refers to a substance that can bind specifically to an 20 antibody or to a T-cell receptor.

Antigens useful in the compositions of the invention include, without limitation, polypeptides, a microorganism or a part thereof, such as a live, attenuated, inactivated or killed bacterium, virus or protozoan, or part thereof.

As used herein and in the claims, the term "antigen" also includes a 25 polynucleotide that encodes the polypeptide that functions as an antigen. Nucleic acid-based vaccination strategies are known, wherein a vaccine composition that contains a polynucleotide is administered to a subject. The antigenic polypeptide encoded by the polynucleotide is expressed in the subject, such that the antigenic polypeptide is ultimately present in the subject, just as if the vaccine composition itself had contained the 30 polypeptide. For the purposes of the present invention, the term "antigen", where the context dictates, encompasses such polynucleotides that encode the polypeptide which functions as the antigen.

Polypeptides or fragments thereof that may be useful as antigens in the invention include, without limitation, those derived from Cholera toxoid, tetanus toxoid, diphtheria toxoid, hepatitis B surface antigen, hemagglutinin, neuraminidase, influenza M protein, PfHRP2, pLDH, aldolase, MSP1, MSP2, AMA1, Der-p-1, Der-f-1, Adipophilin, AFP, 5 AIM-2, ART-4, BAGE,  $\alpha$ -fetoprotein, BCL-2, Bcr-Abl, BING-4, CEA, CPSF, CT, cyclin D1Ep-CAM, EphA2, EphA3, ELF-2, FGF-5, G250, Gonadotropin Releasing Hormone, HER-2, intestinal carboxyl esterase (iCE), IL13Ra2, MAGE-1, MAGE-2, MAGE-3, MART-1, MART-2, M-CSF, MDM-2, MMP-2, MUC-1, NY-EOS-1, MUM-1, MUM-2, MUM-3, p53, PBF, PRAME, PSA, PSMA, RAGE-1, RNF43, RU1, RU2AS, SART-1, SART-2, SART-3, 10 SAGE-1, SCRN 1, SOX2, SOX10, STEAP1, surviving, Telomerase, TGF $\beta$ RII, TRAG-3, TRP-1, TRP-2, TERT and WT1.

Viruses, or parts thereof, useful as antigens in the invention include, without limitation, Cowpoxvirus, Vaccinia virus, Pseudocowpox virus, Human herpesvirus 1, Human herpesvirus 2, Cytomegalovirus, Human adenovirus A-F, Polyomavirus, 15 Human papillomavirus, Parvovirus, Hepatitis A virus, Hepatitis B virus, Hepatitis C virus, Human immunodeficiency virus, Orthoreovirus, Rotavirus, Ebolavirus, parainfluenza virus, influenza A virus, influenza B virus, influenza C virus, Measles virus, Mumps virus, Rubella virus, Pneumovirus, Human respiratory syncytial virus, Rabies virus, California encephalitis virus, Japanese encephalitis virus, Hantaan virus, Lymphocytic 20 choriomeningitis virus, Coronavirus, Enterovirus, Rhinovirus, Poliovirus, Norovirus, Flavivirus, Dengue virus, West Nile virus, Yellow fever virus and varicella.

Bacteria or parts of thereof useful as antigens in the invention include, without limitation, Anthrax, Brucella, Candida, Chlamydia pneumoniae, Chlamydia psittaci, Cholera, Clostridium botulinum, Coccidioides immitis, Cryptococcus, Diphtheria, 25 Escherichia coli O157: H7, Enterohemorrhagic Escherichia coli, Enterotoxigenic Escherichia coli, Haemophilus influenzae, Helicobacter pylori, Legionella, Leptospira, Listeria, Meningococcus, Mycoplasma pneumoniae, Mycobacterium, Pertussis, Pneumonia, Salmonella, Shigella, Staphylococcus, Streptococcus pneumoniae and Yersinia enterocolitica.

30 The antigen may alternatively be of protozoan origin, e.g. Plasmodium falciparum, which causes malaria.

The term "polypeptide" encompasses any chain of amino acids, regardless of length (e.g., at least 6, 8, 10, 12, 14, 16, 18, or 20 amino acids) or post-translational

modification (e.g., glycosylation or phosphorylation), and includes, for example, natural proteins, synthetic or recombinant polypeptides and peptides, denatured polypeptides and peptides, epitopes, hybrid molecules, variants, homologs, analogs, peptoids, peptidomimetics, etc. A variant or derivative therefore includes deletions, including 5 truncations and fragments; insertions and additions, for example conservative substitutions, site-directed mutants and allelic variants; and modifications, including peptoids having one or more non-amino acyl groups (for example, sugar, lipid, etc.) covalently linked to the peptide and post-translational modifications. As used herein, the term "conserved amino acid substitutions" or "conservative substitutions" refers to the 10 substitution of one amino acid for another at a given location in the peptide, where the substitution can be made without substantial loss of the relevant function. In making such changes, substitutions of like amino acid residues can be made on the basis of relative 15 similarity of side-chain substituents, for example, their size, charge, hydrophobicity, hydrophilicity, and the like, and such substitutions may be assayed for their effect on the function of the peptide by routine testing. Specific, non-limiting examples of a conservative substitution include the following examples:

Original Residue	Conservative Substitutions
Ala	Ser
Arg	Lys
20 Asn	Gln, His
Asp	Glu
Cys	Ser
Gln	Asn
Glu	Asp
25 His	Asn; Gln
Ile	Leu, Val
Leu	Ile; Val
Lys	Arg; Gln; Glu

	Met	Leu; Ile
	Phe	Met; Leu; Tyr
	Ser	Thr
	Thr	Ser
5	Trp	Tyr
	Tyr	Trp; Phe
	Val	Ile; Leu

Polypeptides or peptides that have substantial identity to a preferred antigen sequence may be used. Two sequences are considered to have substantial identity if, when optimally aligned (with gaps permitted), they share at least approximately 50% sequence identity, or if the sequences share defined functional motifs. In alternative embodiments, optimally aligned sequences may be considered to be substantially identical (i.e., to have substantial identity) if they share at least 60%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% identity over a specified region. The term "identity" refers to sequence similarity between two polypeptides molecules. Identity can be determined by comparing each position in the aligned sequences. A degree of identity between amino acid sequences is a function of the number of identical or matching amino acids at positions shared by the sequences, for example, over a specified region. Optimal alignment of sequences for comparisons of identity may be conducted using a variety of algorithms, as are known in the art, including the ClustalW program, available at <http://clustalw.genome.ad.jp>, the local homology algorithm of Smith and Waterman, 1981, Adv. Appl. Math 2: 482, the homology alignment algorithm of Needleman and Wunsch, 1970, J. Mol. Biol. 48:443, the search for similarity method of Pearson and Lipman, 1988, Proc. Natl. Acad. Sci. USA 85:2444, and the computerised implementations of these algorithms (such as GAP, BESTFIT, FASTA and TFASTA in the Wisconsin Genetics Software Package, Genetics Computer Group, Madison, WI, U.S.A.). Sequence identity may also be determined using the BLAST algorithm, described in Altschul *et al.*, 1990, J. Mol. Biol. 215:403-10 (using the published default settings). For example, the "BLAST 2 Sequences" tool, available through the National Center for Biotechnology Information (through the internet at <http://www.ncbi.nlm.nih.gov/BLAST/bl2seq/wblast2.cgi>) may be used, selecting the "blastp" program at the following default settings: expect threshold 10;

word size 3; matrix BLOSUM 62; gap costs existence 11, extension 1. In another embodiment, the person skilled in the art can readily and properly align any given sequence and deduce sequence identity and/or homology by mere visual inspection.

Polypeptides and peptides used to practice the invention can be isolated from natural sources, be synthetic, or be recombinantly generated polypeptides. Peptides and proteins can be recombinantly expressed *in vitro* or *in vivo*. The peptides and polypeptides used to practice the invention can be made and isolated using any method known in the art. Polypeptide and peptides used to practice the invention can also be synthesized, whole or in part, using chemical methods well known in the art. See e.g., Caruthers (1980) Nucleic Acids Res. Symp. Ser. 215-223; Hom (1980) Nucleic Acids Res. Symp. Ser. 225-232; Banga, A. K, Therapeutic Peptides and Proteins, Formulation, Processing and Delivery Systems (1995) Technomic Publishing Co., Lancaster, Pa. For example, peptide synthesis can be performed using various solid-phase techniques (see e.g., Roberge (1995) Science 269:202; Merrifield (1997) Methods Enzymol. 289:3-13) and automated synthesis may be achieved, e.g., using the ABI 431A Peptide Synthesizer (Perkin Elmer) in accordance with the instructions provided by the manufacturer.

In some embodiments, the antigen may be a purified antigen, e.g., from about 25% to 50% pure, from about 50% to about 75% pure, from about 75% to about 85% pure, from about 85% to about 90% pure, from about 90% to about 95% pure, from about 95% to about 98% pure, from about 98% to about 99% pure, or greater than 99% pure.

As noted above, the term "antigen" also includes a polynucleotide that encodes the polypeptide that functions as an antigen. Nucleic acid-based vaccination strategies are known, wherein a vaccine composition that contains a polynucleotide is administered to a subject. The antigenic polypeptide encoded by the polynucleotide is expressed in the subject, such that the antigenic polypeptide is ultimately present in the subject, just as if the vaccine composition itself had contained the polypeptide. For the purposes of the present invention, the term "antigen", where the context dictates, encompasses such polynucleotides that encode the polypeptide which functions as the antigen.

As used herein and in the claims, the term "polynucleotide" encompasses a chain of nucleotides of any length (e.g. 9, 12, 18, 24, 30, 60, 150, 300, 600, 1500 or more nucleotides) or number of strands (e.g. single-stranded or double-stranded).

Polynucleotides may be DNA (e.g. genomic DNA or cDNA) or RNA (e.g. mRNA) or combinations thereof. They may be naturally occurring or synthetic (e.g. chemically synthesized). It is contemplated that the polynucleotide may contain modifications of one or more nitrogenous bases, pentose sugars or phosphate groups in the nucleotide chain.

5 Such modifications are well-known in the art and may be for the purpose of e.g. improving stability of the polynucleotide.

The polynucleotide may be delivered in various forms. In some embodiments, a naked polynucleotide may be used, either in linear form, or inserted into a plasmid, such as an expression plasmid. In other embodiments, a live vector such as a

10 viral or bacterial vector may be used.

One or more regulatory sequences that aid in transcription of DNA into RNA and/or translation of RNA into a polypeptide may be present. In some instances, such as in the case of a polynucleotide that is a messenger RNA (mRNA) molecule, regulatory sequences relating to the transcription process (e.g. a promoter) are not

15 required, and protein expression may be effected in the absence of a promoter. The skilled artisan can include suitable regulatory sequences as the circumstances require.

In some embodiments, the polynucleotide is present in an expression cassette, in which it is operably linked to regulatory sequences that will permit the polynucleotide to be expressed in the subject to which the composition of the invention is

20 administered. The choice of expression cassette depends on the subject to which the composition is administered as well as the features desired for the expressed polypeptide.

Typically, an expression cassette includes a promoter that is functional in the subject and can be constitutive or inducible; a ribosome binding site; a start codon (ATG) if necessary; the polynucleotide encoding the polypeptide of interest; a stop codon;

25 and optionally a 3' terminal region (translation and/or transcription terminator). Additional sequences such as a region encoding a signal peptide may be included. The polynucleotide encoding the polypeptide of interest may be homologous or heterologous to any of the other regulatory sequences in the expression cassette. Sequences to be expressed together with the polypeptide of interest, such as a signal peptide encoding

30 region, are typically located adjacent to the polynucleotide encoding the protein to be expressed and placed in proper reading frame. The open reading frame constituted by the polynucleotide encoding the protein to be expressed solely or together with any other sequence to be expressed (e.g. the signal peptide), is placed under the control of the

promoter so that transcription and translation occur in the subject to which the composition is administered.

In a related embodiment, the antigen may be an allergen and may be derived from, without limitation, cells, cell extracts, proteins, polypeptides, peptides, 5 polysaccharides, polysaccharide conjugates, peptide and non-peptide mimics of polysaccharides and other molecules, small molecules, lipids, glycolipids, and carbohydrates of plants, animals, fungi, insects, food, drugs, dust, and mites. Allergens include but are not limited to environmental aeroallergens; plant pollens (e.g. ragweed / hayfever); weed pollen allergens; grass pollen allergens; Johnson grass; tree pollen 10 allergens; ryegrass; arachnid allergens (e.g. house dust mite allergens); storage mite allergens; Japanese cedar pollen / hay fever; mold / fungal spore allergens; animal allergens (e.g., dog, guinea pig, hamster, gerbil, rat, mouse, etc., allergens); food allergens (e.g. crustaceans; nuts; citrus fruits; flour; coffee); insect allergens (e.g. fleas, cockroach); venoms: (Hymenoptera, yellow jacket, honey bee, wasp, hornet, fire ant); 15 bacterial allergens (e.g. streptococcal antigens; parasite allergens such as Ascaris antigen); viral antigens; drug allergens (e.g. penicillin); hormones (e.g. insulin); enzymes (e.g. streptokinase); and drugs or chemicals capable of acting as incomplete antigens or haptens (e.g. the acid anhydrides and the isocyanates).

#### PolyI:C Polynucleotides

20 PolyI:C polynucleotides are double stranded polynucleotide molecules (either RNA or DNA or a combination of DNA and RNA) containing inosinic acid residues (I) and cytidylic acid residues (C), and which induce the production of inflammatory cytokines, such as interferon. They are typically composed of one strand consisting entirely of cytosine-containing nucleotides and one strand consisting entirely of inosine- 25 containing nucleotides although other configurations are possible. For instance, each strand may contain both cytosine-containing and inosine-containing nucleotides. In some instances, either or both strand may additionally contain one or more non-cytosine or non-inosine nucleotides.

It has been reported that polyI:C can be segmented every 16 residues 30 without an effect on its interferon activating potential (Bobst, 1981). Furthermore, the interferon inducing potential of a polyI:C molecule mismatched by introducing a uridine residue every 12 repeating cytidylic acid residues (Hendrix, 1993), suggests that a minimal double stranded polyI:C molecule of 12 residues is sufficient to promote

interferon production. Others have also suggested that regions as small as 6-12 residues, which correspond to 0.5-1 helical turn of the double stranded polynucleotide, are capable of triggering the induction process (Greene, 1978). If synthetically made, polyI:C polynucleotides are typically about 20 or more residues in length (commonly 22, 5 24, 26, 28 or 30 residues in length). If semisynthetically made (e.g. using an enzyme), the length of the strand may be 500, 1000 or more residues.

PolyI:C act as mimics of viral genomes and are particularly useful for modulating the immune system *in vivo*. Synthetic poly I:poly C homopolymers for example has been reported to enhance innate immunity by inducing interferon gamma 10 non-specifically when delivered systemically *in vivo* by intravenous or intramuscular injection (Krown 1985, Zhu 2007). Several variants of poly inosinic and cytidylic acid polymers have been described over the years (de Clercq 1978, Bobst 1981, De Clercq 1975, Guschlauer 1977, Fukui 1977, Johnston 1975, US3906092 1971, Kamath 2008, Ichinohe 2007), some of which included the use of covalently modified residues, the use 15 of ribo and deoxy-ribo inosinic and cytidylic residues, the use of homopolymers and alternating co-polymers that contain inosinic and cytidylic acid residues, and the introduction of specific residues to create mismatched polymers.

The use of double stranded polynucleotides containing inosinic and cytidylic acids has been reported for the treatment of a number of viral diseases (Kende 20 1987, Poast 2002, 6,468,558 2002, Sarma 1969, Stephen 1977, Levy 1978), cancer (Durie 1985, Salazar 1996, Theriault 1986, Nakamura 1982, Talmadge 1985, Droller 1987), autoimmune disease like multiple sclerosis (Bever 1986), and other infectious 25 diseases such as malaria (Awasthi 1997, Puri 1996). The efficacy of polyI:C molecules has been further enhanced in some cases by complexing the molecule with positively charged poly-lysine and carboxymethyl-cellulose, effectively protecting the polynucleotide from nuclease degradation *in vivo* (Stephen 1977, Levy 1985), or by complexing polyI:C with positively charged synthetic peptides (Schellack 2006).

In addition to its uses as a non-specific enhancer of innate immunity, polyI:C is also useful as adjuvant in vaccine compositions. The enhancement of innate 30 immunity can lead to an enhanced antigen specific adaptive immunity, possibly through a mechanism that involves, at least in part, NK cells, macrophages and/or dendritic cells (Chirigos 1985, Salem 2006, Alexopoulou 2001, Trumpheller 2008). Evidence for the use of polyI:C molecules in this context originates from various vaccine studies for controlling infectious diseases (Houston 1976, Stephen 1977, Ichinohe 2007, Sloat 2008,

Agger 2006, Padalko 2004) and the prevention or treatment of cancer by a variety of vaccine modalities (Zhu 2007, Cui 2006, Salem 2005, Fujimura 2006, Llopiz 2008).

These studies demonstrate that polyI:C enhances humoral responses as evident from enhanced antibody responses against specific infectious disease antigens. PolyI:C is

5 also a potentiator of antigen-specific cellular responses (Zhu 2007, Zaks 2006, Cui 2006, Riedl 2008). The adjuvanting effects of PolyI:C molecules are believed to occur, at least partially, by inducing interferon-gamma through their interaction with toll like receptors (TLR) such as TLR3, TLR4, TLR7, TLR8 and TLR9 (Alexopoulou 2001, Trumpheller 2008, Schellack 2006, Riedl 2008), with TLR3 being particularly relevant for most polyI:C  
10 molecules. Evidence also suggests that polyI:C molecules may exert their effect, at least in part, by interacting with receptors other than TLRs, such as the RNA helicase retinoic acid induced protein I (RIG-I)/melanoma differentiation associated gene 5 (MDA5) (Alexopoulou 2001, Yoneyama 2004, Gowen 2007, Dong 2008). The mechanism of action of polyI:C molecules remains to be fully understood.

15 Accordingly, as used herein, a "polyI:C" or "polyI:C polynucleotide" is a double-stranded polynucleotide molecule (RNA or DNA or a combination of DNA and RNA), each strand of which contains at least 6 contiguous inosinic or cytidylic acid residues, or 6 contiguous residues selected from inosinic acid and cytidylic acid in any order (e.g. IICIIIC or ICICIC), and which is capable of inducing or enhancing the  
20 production of at least one inflammatory cytokine, such as interferon, in a mammalian subject. PolyI:C polynucleotides will typically have a length of about 8, 10, 12, 14, 16, 18, 20, 22, 24, 25, 28, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 150, 200, 250, 300, 500, 1000 or more residues. The upper limit is not believed to be essential. Preferred polyI:C polynucleotides may have a minimum length of about 6, 8, 10, 12, 14,  
25 16, 18, 20, 22, 24, 26, 28, or 30 nucleotides and a maximum length of about 1000, 500, 300, 200, 100, 90, 80, 70, 60, 50, 45 or 40 nucleotides.

Each strand of a polyI:C polynucleotide may be a homopolymer of inosinic or cytidylic acid residues, or each strand may be a heteropolymer containing both inosinic and cytidylic acid residues. In either case, the polymer may be interrupted by one or  
30 more non-inosinic or non-cytidylic acid residues (e.g. uridine), provided there is at least one contiguous region of 6 I, 6 C or 6 I/C residues as described above. Typically, each strand of a polyI:C polynucleotide will contain no more than 1 non-I/C residue per 6 I/C residues, more preferably, no more than 1 non-I/C residue per every 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28 or 30 I/C residues.

The inosinic acid or cytidylic acid (or other) residues in the polyI:C polynucleotide may be derivatized or modified as is known in the art, provided the ability of the polyI:C polynucleotide to promote the production of an inflammatory cytokine, such as interferon, is retained. Non-limiting examples of derivatives or modifications include

5 e.g. azido modifications, fluoro modifications, or the use of thioester (or similar) linkages instead of natural phosphodiester linkages to enhance stability *in vivo*. The polyI:C polynucleotide may also be modified to e.g. enhance its resistance to degradation *in vivo* by e.g. complexing the molecule with positively charged poly-lysine and carboxymethylcellulose, or with a positively charged synthetic peptide.

10 The polyI:C polynucleotide will typically be included in the compositions of the invention in an amount from about 0.001 mg to 1 mg per unit dose of the composition.

### Liposomes

Liposomes are completely closed lipid bilayer membranes containing an entrapped aqueous volume. Liposomes may be unilamellar vesicles (possessing a single

15 bilayer membrane) or multilamellar vesicles characterized by multimembrane bilayers, each bilayer may or may not be separated from the next by an aqueous layer. A general discussion of liposomes can be found in Gregoriadis G. *Immunol. Today*, 11:89-97, 1990; and Frezard, F., *Braz. J. Med. Bio. Res.*, 32:181-189, 1999. As used herein and in the claims, the term "liposomes" is intended to encompass all such vesicular structures as

20 described above, including, without limitation, those described in the art as "niosomes", "transfersomes" and "virosomes".

Although any liposomes may be used in this invention, including liposomes made from archaebacterial lipids, particularly useful liposomes use phospholipids and unesterified cholesterol in the liposome formulation. The cholesterol is used to stabilize

25 the liposomes and any other compound that stabilizes liposomes may replace the cholesterol. Other liposome stabilizing compounds are known to those skilled in the art. For example, saturated phospholipids produce liposomes with higher transition temperatures indicating increased stability.

Phospholipids that are preferably used in the preparation of liposomes are

30 those with at least one head group selected from the group consisting of phosphoglycerol, phosphoethanolamine, phosphoserine, phosphocholine and phosphoinositol. More preferred are liposomes that comprise lipids which are 94-100% phosphatidylcholine. Such lipids are available commercially in the lecithin Phospholipon® 90 G. When

unesterified cholesterol is also used in liposome formulation, the cholesterol is used in an amount equivalent to about 10% of the amount of phospholipid. If a compound other than cholesterol is used to stabilize the liposomes, one skilled in the art can readily determine the amount needed in the composition.

5                    Liposome compositions may be obtained, for example, by using natural lipids, synthetic lipids, sphingolipids, ether lipids, sterols, cardiolipin, cationic lipids and lipids modified with poly (ethylene glycol) and other polymers. Synthetic lipids may include the following fatty acid constituents; lauroyl, myristoyl, palmitoyl, stearoyl, arachidoyl, oleoyl, linoleoyl, erucoyl, or combinations of these fatty acids.

10    Carriers

The carrier of the composition comprises a continuous phase of a hydrophobic substance, preferably a liquid hydrophobic substance. The continuous phase may be an essentially pure hydrophobic substance or a mixture of hydrophobic substances. In addition, the carrier may be an emulsion of water in a hydrophobic 15 substance or an emulsion of water in a mixture of hydrophobic substances, provided the hydrophobic substance constitutes the continuous phase. Further, in another embodiment, the carrier may function as an adjuvant.

Hydrophobic substances that are useful in the compositions as described herein are those that are pharmaceutically and/or immunologically acceptable. The 20 carrier is preferably a liquid but certain hydrophobic substances that are not liquids at atmospheric temperature may be liquefied, for example by warming, and are also useful in this invention. In one embodiment, the hydrophobic carrier may be a Phosphate Buffered Saline/Freund's Incomplete Adjuvant (PBS/FIA) emulsion.

Oil or water-in-oil emulsions are particularly suitable carriers for use in the 25 present invention. Oils should be pharmaceutically and/or immunologically acceptable. Suitable oils include, for example, mineral oils (especially light or low viscosity mineral oil such as Drakeol® 6VR), vegetable oils (e.g., soybean oil), nut oils (e.g., peanut oil), or mixtures thereof. In an embodiment, the oil is a mannide oleate in mineral oil solution, commercially available as Montanide® ISA 51. Animal fats and artificial hydrophobic 30 polymeric materials, particularly those that are liquid at atmospheric temperature or that can be liquefied relatively easily, may also be used.

Other Components

The composition may further comprise one or more pharmaceutically acceptable adjuvants, excipients, etc., as are known in the art: See, for example, Remington's Pharmaceutical Sciences (Remington's Pharmaceutical Sciences, Mack Publishing Company, Easton, Pa., USA 1985) and The United States Pharmacopoeia: The National Formulary (USP 24 NF19) published in 1999.

The term "adjuvant" refers to a compound or mixture that enhances the immune response to an antigen. An adjuvant can serve as a tissue depot that slowly releases the antigen and also as a lymphoid system activator that non-specifically enhances the immune response (Hood et al, Immunology, 2d ed., Benjamin/Cummings: Menlo Park, C.A., 1984; see Wood and Williams, In: Nicholson, Webster and May (eds.), Textbook of Influenza, Chapter 23, pp. 317-323). Often, a primary challenge with an antigen alone, in the absence of an adjuvant, will fail to elicit a humoral immune response.

Suitable adjuvants include, but are not limited to, alum, other compounds of aluminum, *Bacillus of Calmette and Guerin* (BCG), TiterMax®, Ribi®, incomplete Freund's adjuvant (IFA), saponin, surface active substances such as lysolecithin, pluronic polyols, polyanions, peptides, *Corynebacteriumparvum*, QS-21, Freund's Complete Adjuvant (FCA), adjuvants of the TLR agonist family such as CpG, falgellin, lipopeptides, peptidoglycans, imidazoquinolines, single stranded RNA, lipopolysaccharides (LPS), heat shock proteins (HSP), and ceramides and derivatives such as  $\alpha$ Gal-cer. Suitable adjuvants also include cytokines or chemokines in their polypeptide or DNA coding forms such as, but not limited to, GM-CSF, TNF- $\alpha$ , IFN- $\gamma$ , IL-2, IL-12, IL-15, IL-21. A suitable alum adjuvant is sold under the trade name Imject Alum® (Pierce, Rockford, IL), that consists of an aqueous solution of aluminum hydroxide (45 mg/ml) and magnesium hydroxide (40 mg/ml) plus inactive stabilizers.

The amount of adjuvant used depends on the amount of antigen and on the type of adjuvant. One skilled in the art can readily determine the amount of adjuvant needed in a particular application.

An immune response elicited in subjects administered a composition of the invention may be formulated to bias the immune response towards an antibody or a cell mediated immune response. This may be achieved by using agents, such as adjuvants, that predominantly induce a Th1 or Th2 response. For example, a CpG-containing

oligonucleotides (in which the CpG dinucleotide is unmethylated) may be used to induce a predominantly Th1 response, thus favouring a cell mediated response.

### Compositions

Methods for making liposomes are well known in the art. See e.g.

- 5 Gregoriadis (1990) and Frezard (1999) both cited previously. Any suitable method for making liposomes may be used in the practice of the invention, or liposomes may be obtained from a commercial source. Liposomes are typically prepared by hydrating the liposome components that will form the lipid bilayer (e.g. phospholipids and cholesterol) with an aqueous solution, which may be pure water or a solution of one or more
- 10 components dissolved in water, e.g. phosphate-buffered saline (PBS), phosphate-free saline, or any other physiologically compatible aqueous solution.

In an embodiment, a liposome component or mixture of liposome components, such as a phospholipid (e.g. Phospholipon® 90G) and cholesterol, may be solubilized in an organic solvent, such as a mixture of chloroform and methanol, followed by filtering (e.g. a PTFE 0.2  $\mu\text{m}$  filter) and drying, e.g. by rotary evaporation, to remove the solvents.

Hydration of the resulting lipid mixture may be effected by e.g. injecting the lipid mixture into an aqueous solution or sonicating the lipid mixture and an aqueous solution. During formation of liposomes, the liposome components form single bilayers

- 20 (unilamellar) or multiple bilayers (multilamellar) surrounding a volume of the aqueous solution with which the liposome components are hydrated.

In some embodiments, the liposomes are then dehydrated, such as by freeze-drying or lyophilization.

The liposomes are combined with the carrier comprising a continuous

- 25 hydrophobic phase. This can be done in a variety of ways.

If the carrier is composed solely of a hydrophobic substance or a mixture of hydrophobic substances (e.g. use of a 100% mineral oil carrier), the liposomes may simply be mixed with the hydrophobic substance, or if there are multiple hydrophobic substances, mixed with any one or a combination of them.

30 If instead the carrier comprising a continuous phase of a hydrophobic substance contains a discontinuous aqueous phase, the carrier will typically take the form

of an emulsion of the aqueous phase in the hydrophobic phase, such as a water-in-oil emulsion. Such compositions may contain an emulsifier to stabilize the emulsion and to promote an even distribution of the liposomes. In this regard, emulsifiers may be useful even if a water-free carrier is used, for the purpose of promoting an even distribution of 5 the liposomes in the carrier. Typical emulsifiers include mannide oleate (Arlacel<sup>TM</sup> A), lecithin, Tween<sup>TM</sup> 80, and Spans<sup>TM</sup> 20, 80, 83 and 85. Typically, the volume ratio (v/v) of hydrophobic substance to emulsifier is in the range of about 5:1 to about 15:1 with a ratio of about 10:1 being preferred.

10 The liposomes may be added to the finished emulsion, or they may be present in either the aqueous phase or the hydrophobic phase prior to emulsification.

The antigen may be introduced at various different stages of the formulation process. More than one type of antigen may be incorporated into the composition (e.g. an inactivated virus, attenuated live virus, protein or polypeptide).

15 In some embodiments, the antigen is present in the aqueous solution used to hydrate the components that are used to form the lipid bilayers of the liposomes (e.g. phospholipid(s) and cholesterol). In this case, the antigen will be encapsulated in the liposome, present in its aqueous interior. If the resulting liposomes are not washed or dried, such that there is residual aqueous solution present that is ultimately mixed with the carrier comprising a continuous phase of a hydrophobic substance, it is possible that 20 additional antigen may be present outside the liposomes in the final product. In a related technique, the antigen may be mixed with the components used to form the lipid bilayers of the liposomes, prior to hydration with the aqueous solution.

25 In an alternative approach, the antigen may instead be mixed with the carrier comprising a continuous phase of a hydrophobic substance, before, during, or after the carrier is combined with the liposomes. If the carrier is an emulsion, the antigen may be mixed with either or both of the aqueous phase or hydrophobic phase prior to emulsification. Alternatively, the antigen may be mixed with the carrier after emulsification.

30 The technique of combining the antigen with the carrier may be used together with encapsulation of the antigen in the liposomes as described above, such that antigen is present both within the liposomes and in the carrier comprising a continuous phase of a hydrophobic substance.

The above-described procedures for introducing the antigen into the composition apply also to the polyI:C. That is, the polyI:C may be introduced into e.g. any one or more of: (1) the aqueous solution used to hydrate the components that are used to form the lipid bilayers of the liposomes; (2) the components used to form the lipid bilayers of the liposomes; or (3) the carrier comprising a continuous phase of a hydrophobic substance, before, during, or after the carrier is combined with the liposomes. If the carrier is an emulsion, the polyI:C may be mixed with either or both of the aqueous phase or hydrophobic phase prior to emulsification. Alternatively, the polyI:C may be mixed with the carrier after emulsification.

10 The technique of combining the polyI:C with the carrier may be used together with encapsulation of the polyI:C in the liposomes, such that polyI:C is present both within the liposomes and in the carrier comprising a continuous phase of a hydrophobic substance.

15 The polyI:C can be incorporated in the composition together with the antigen at the same processing step, or separately, at a different processing step. For instance, the antigen and the polyI:C may both be present in the aqueous solution used to hydrate the lipid bilayer-forming liposome components, such that both the antigen and polyI:C become encapsulated in the liposomes. Alternatively, the antigen may be encapsulated in the liposomes, and the polyI:C mixed with the carrier comprising a 20 continuous phase of a hydrophobic substance. It will be appreciated that many such combinations are possible.

25 If the composition contains one or more adjuvants, the adjuvant can be incorporated in the composition together with the antigen at the same processing step, or separately, at a different processing step. For instance, the antigen and adjuvant may both be present in the aqueous solution used to hydrate the lipid bilayer-forming liposome components, such that both the antigen and adjuvant become encapsulated in the liposomes. Alternatively, the antigen may be encapsulated in the liposomes, and the adjuvant mixed with the carrier comprising a continuous phase of a hydrophobic substance.

30 Stabilizers such as sugars, anti-oxidants, or preservatives that maintain the biological activity or improve chemical stability to prolong the shelf life of antigen, adjuvant, the liposomes or the continuous hydrophobic carrier, may be added to such compositions.

In some embodiments, an antigen/polyI:C mixture may be used, in which case the antigen and the polyI:C polynucleotide are incorporated into the composition at the same time. An “antigen/polyI:C mixture” refers to an embodiment in which the antigen and polyI:C polynucleotide are in the same diluent at least prior to incorporation into the composition. The antigen and polyI:C polynucleotide in an antigen/polyI:C mixture may, but need not necessarily be chemically linked, such as by covalent bonding.

Similarly, in some embodiments, an antigen/adjuvant mixture may be used, in which case the antigen and adjuvant are incorporated into the composition at the same time. An “antigen/adjuvant mixture” refers to an embodiment in which the antigen and adjuvant are in the same diluent at least prior to incorporation into the composition. The antigen and adjuvant in an antigen/adjuvant mixture may, but need not necessarily be chemically linked, such as by covalent bonding.

In some embodiments, the carrier comprising a continuous phase of a hydrophobic substance may itself have adjuvanting-activity. Incomplete Freund's adjuvant, is an example of a hydrophobic carrier with adjuvanting effect. As used herein and in the claims, when the term “adjuvant” is used, this is intended to indicate the presence of an adjuvant in addition to any adjuvanting activity provided by the carrier comprising a continuous phase of a hydrophobic substance.

The compositions as described herein may be formulated in a form that is suitable for oral, nasal, rectal or parenteral administration. Parenteral administration includes intravenous, intraperitoneal, intradermal, subcutaneous, intramuscular, transepithelial, intrapulmonary, intrathecal, and topical modes of administration. Preferred routes include intramuscular, subcutaneous and intradermal administration to achieve a depot effect. In embodiments where the composition of the invention is for the treatment of cancer tumors, the composition may be formulated for delivery by injection directly into the tumor, or adjacent to the tumor. In some embodiments, the composition may be delivered evenly over or throughout the tumor to enhance the biodistribution and hence enhance the therapeutic benefit.

In further embodiments, a composition of the invention may be formulated with DNA based polyI:C, RNA based polyI:C or a mixture of RNA and DNA based polyI:C. In this context, a RNA and DNA mixture may relate to nucleotides, such that each strand may comprises DNA and RNA nucleotides; to the strands, such that each double stranded polynucleotide has one DNA strand and one RNA strand; to the polynucleotide,

such that a composition contains polyI:C polynucleotides, each of which are wholly composed of RNA or wholly composed of DNA; or combinations thereof.

In other embodiments, the compositions of the invention may be formulated for use in combination with a T cell epitope or a B cell epitope. The T cell epitope may be a universal T cell epitope and the B cell epitope may be a universal B cell epitope. As used herein, a "universal epitope" may be any epitope that is broadly recognized, for example, by T cells or B cells of multiple strains of an animal. In one embodiment, the T cell epitope may be a tetanus toxoid peptide such as F21E. In another embodiment, the T cell epitope may be PADRE, a universal helper T cell epitope.

10 Other universal epitopes that may be suitable for use in the context of the invention are known to the skilled person or may be readily identified using routine techniques.

In related embodiments, a composition of the invention comprises a polyI:C polynucleotide and an antigen, where the presence of the polyI:C polynucleotide and the antigen in terms of weight or number of molecules is in a ratio of less than 1 to 15 1,000, of less than 1 to 900, of less than 1 to 800, of less than 1 to 700, of less than 1 to 500, of less than 1 to 400, of less than 1 to 300, of less than 1 to 200, of less than 1 to 100, of less than 1 to 50, of less than 1 to 10, of less than 1 to 5, of less than 1 to 2, of about 1 to 1, of greater than 2 to 1, of greater than 5 to 1, of greater than 10 to 1, of greater than 50 to 1, of greater than 100 to 1, of greater than 200 to 1, of greater than 300 20 to 1, of greater than 400 to 1, of greater than 500 to 1, of greater than 600 to 1, of greater than 700 to 1, of greater than 800 to 1, of greater than 900 to 1, of greater than 1,000 to 1.

The optimal amount of polyI:C polynucleotide to antigen to elicit an optimal immune response may depend on a number of factors including, without limitation, the 25 composition, the disease, the subject, and may be readily ascertained by the skilled person using standard studies including, for example, observations of antibody titers and other immunogenic responses in the host.

#### Kits and Reagents

The present invention is optionally provided to a user as a kit. For 30 example, a kit of the invention contains one or more of the compositions of the invention. The kit can further comprise one or more additional reagents, packaging material, containers for holding the components of the kit, and an instruction set or user manual detailing preferred methods of using the kit components.

Methods of Use

The invention finds application in any instance in which it is desired to administer an antigen to a subject. The subject may be a vertebrate, such as a fish, bird or mammal, preferably a human.

5 In some embodiments, the compositions of the invention may be administered to a subject in order to elicit and/or enhance an antibody response to the antigen.

As used herein, to "elicit" an immune response is to induce and/or potentiate an immune response. As used herein, to "enhance" an immune response is to 10 elevate, improve or strengthen the immune response to the benefit of the host relative to the prior immune response status, for example, before the administration of a composition of the invention.

An "antibody" is a protein comprising one or more polypeptides substantially or partially encoded by immunoglobulin genes or fragments of 15 immunoglobulin genes. The recognized immunoglobulin genes include the  $\kappa$ ,  $\lambda$ ,  $\alpha$ ,  $\gamma$ ,  $\delta$ ,  $\epsilon$  and  $\mu$  constant region genes, as well as myriad immunoglobulin variable region genes. Light chains are classified as either  $\kappa$  or  $\lambda$ . Heavy chains are classified as  $\gamma$ ,  $\mu$ ,  $\alpha$ ,  $\delta$ , or  $\epsilon$ , which in turn define the immunoglobulin classes, IgG, IgM, IgA, IgD and IgE, respectively. A typical immunoglobulin (antibody) structural unit comprises a protein containing four 20 polypeptides. Each antibody structural unit is composed of two identical pairs of polypeptide chains, each having one "light" and one "heavy" chain. The N-terminus of each chain defines a variable region primarily responsible for antigen recognition. Antibody structural units (e.g. of the IgA and IgM classes) may also assemble into oligomeric forms with each other and additional polypeptide chains, for example as IgM 25 pentamers in association with the J-chain polypeptide.

Antibodies are the antigen-specific glycoprotein products of a subset of white blood cells called B lymphocytes (B cells). Engagement of antigen with antibody expressed on the surface of B cells can induce an antibody response comprising stimulation of B cells to become activated, to undergo mitosis and to terminally 30 differentiate into plasma cells, which are specialized for synthesis and secretion of antigen-specific antibody.

As used herein, the term "antibody response" refers to an increase in the amount of antigen-specific antibodies in the body of a subject in response to introduction of the antigen into the body of the subject.

One method of evaluating an antibody response is to measure the titers of antibodies reactive with a particular antigen. This may be performed using a variety of methods known in the art such as enzyme-linked immunosorbent assay (ELISA) of antibody-containing substances obtained from animals. For example, the titers of serum antibodies which bind to a particular antigen may be determined in a subject both before and after exposure to the antigen. A statistically significant increase in the titer of antigen-specific antibodies following exposure to the antigen would indicate the subject had mounted an antibody response to the antigen.

Other assays that may be used to detect the presence of an antigen-specific antibody include, without limitation, immunological assays (e.g. radioimmunoassay (RIA)), immunoprecipitation assays, and protein blot (e.g. Western blot) assays; and neutralization assays (e.g., neutralization of viral infectivity in an *in vitro* or *in vivo* assay).

In some embodiments, the compositions of the invention may be administered to a subject in order to elicit and/or enhance a cell-mediated immune response to the antigen. As used herein, the term "cell-mediated immune response" refers to an increase in the amount of antigen-specific cytotoxic T-lymphocytes, macrophages, natural killer cells, or cytokines in the body of a subject in response to introduction of the antigen into the body of the subject.

Historically, the immune system was separated into two branches: humoral immunity, for which the protective function of immunization could be found in the humor (cell-free bodily fluid or serum that contain antibodies) and cellular immunity, for which the protective function of immunization was associated with cells. Cell-mediated immunity is an immune response that involves the activation of macrophages, natural killer cells (NK), antigen-specific cytotoxic T-lymphocytes, and the release of various cytokines in response to a 'non-self' antigen. Cellular immunity is an important component of adaptive immune response and following recognition of antigen by cells through their interaction with antigen-presenting cells such as dendritic cells, B lymphocytes and to a lesser extent, macrophages, protects the body by various mechanisms such as:

1. activating antigen-specific cytotoxic T-lymphocytes that are able to induce apoptosis in body cells displaying epitopes of foreign antigen on their surface, such as virus-infected cells, cells with intracellular bacteria, and cancer cells displaying tumor antigens;
- 5 2. activating macrophages and natural killer cells, enabling them to destroy intracellular pathogens; and
3. stimulating cells to secrete a variety of cytokines that influence the function of other cells involved in adaptive immune responses and innate immune responses.

Cell-mediated immunity is most effective in removing virus-infected cells, 10 but also participates in defending against fungi, protozoans, cancers, and intracellular bacteria. It also plays a major role in transplant rejection.

#### Detection of cell mediated immune response following vaccination

Since cell mediated immunity involves the participation of various cell types and is mediated by different mechanisms, several methods could be used to demonstrate 15 the induction of immunity following vaccination. These could be broadly classified into detection of: i) specific antigen presenting cells; ii) specific effector cells and their functions and iii) release of soluble mediators such as cytokines.

i) Antigen presenting cells: Dendritic cells and B-cells (and to a lesser extent macrophages) are equipped with special immuno-stimulatory receptors that allow for 20 enhanced activation of T cells, and are termed professional antigen presenting cells (APC). These immuno-stimulatory molecules (also called as co-stimulatory molecules) are up-regulated on these cells following infection or vaccination, during the process of antigen presentation to effector cells such as CD4 and CD8 cytotoxic T cells. Such co-stimulatory molecules (such as CD80, CD86, MHC class I or MHC class II) can be 25 detected by using flow cytometry with fluorochrome-conjugated antibodies directed against these molecules along with antibodies that specifically identify APC (such as CD11c for dendritic cells).

ii) Cytotoxic T cells: (also known as Tc, killer T cell, or cytotoxic T-lymphocyte (CTL)) are 30 a sub-group of T cells which induce the death of cells that are infected with viruses (and other pathogens), or expressing tumor antigens. These CTLs directly attack other cells carrying certain foreign or abnormal molecules on their surface. The ability of such

cellular cytotoxicity can be detected using *in vitro* cytolytic assays (chromium release assay). Thus, induction of adaptive cellular immunity can be demonstrated by the presence of such cytotoxic T cells, wherein, when antigen loaded target cells are lysed by specific CTLs that are generated *in vivo* following vaccination or infection.

5                   Naive cytotoxic T cells are activated when their T-cell receptor (TCR) strongly interacts with a peptide-bound MHC class I molecule. This affinity depends on the type and orientation of the antigen/MHC complex, and is what keeps the CTL and infected cell bound together. Once activated the CTL undergoes a process called clonal expansion in which it gains functionality, and divides rapidly, to produce an army of  
10                “armed”-effector cells. Activated CTL will then travel throughout the body in search of cells bearing that unique MHC Class I + peptide. This could be used to identify such CTLs *in vitro* by using peptide-MHC Class I tetramers in flow cytometric assays.

When exposed to these infected or dysfunctional somatic cells, effector CTL release perforin and granzysin: cytotoxins which form pores in the target cell's  
15                plasma membrane, allowing ions and water to flow into the infected cell, and causing it to burst or lyse. CTL release granzyme, a serine protease that enters cells via pores to induce apoptosis (cell death). Release of these molecules from CTL can be used as a measure of successful induction of cellular immune response following vaccination. This can be done by enzyme linked immunosorbant assay (ELISA) or enzyme linked  
20                immunospot assay (ELISPOT) where CTLs can be quantitatively measured. Since CTLs are also capable of producing important cytokines such as IFN- $\gamma$ , quantitative measurement of IFN- $\gamma$ -producing CD8 cells can be achieved by ELISPOT and by flowcytometric measurement of intracellular IFN- $\gamma$  in these cells.

CD4+ “helper” T-cells: CD4+ lymphocytes, or helper T cells, are immune response  
25                mediators, and play an important role in establishing and maximizing the capabilities of the adaptive immune response. These cells have no cytotoxic or phagocytic activity; and cannot kill infected cells or clear pathogens, but, in essence “manage” the immune response, by directing other cells to perform these tasks. Two types of effector CD4+ T helper cell responses can be induced by a professional APC, designated Th1 and Th2,  
30                each designed to eliminate different types of pathogens.

Helper T cells express T-cell receptors (TCR) that recognize antigen bound to Class II MHC molecules. The activation of a naive helper T-cell causes it to release cytokines, which influences the activity of many cell types, including the APC that

activated it. Helper T-cells require a much milder activation stimulus than cytotoxic T-cells. Helper T-cells can provide extra signals that "help" activate cytotoxic cells. Two types of effector CD4+ T helper cell responses can be induced by a professional APC, designated Th1 and Th2, each designed to eliminate different types of pathogens. The 5 two Th cell populations differ in the pattern of the effector proteins (cytokines) produced. In general, Th1 cells assist the cellular immune response by activation of macrophages and cytotoxic T-cells; whereas Th2 cells promote the humoral immune response by stimulation of B-cells for conversion into plasma cells and by formation of antibodies. For example, a response regulated by Th1 cells may induce IgG2a and IgG2b in mouse 10 (IgG1 and IgG3 in humans) and favor a cell mediated immune response to an antigen. If the IgG response to an antigen is regulated by Th2 type cells, it may predominantly enhance the production of IgG1 in mouse (IgG2 in humans). The measure of cytokines associated with Th1 or Th2 responses will give a measure of successful vaccination. This 15 can be achieved by specific ELISA designed for Th1-cytokines such as IFN- $\gamma$ , IL-2, IL-12, TNF- $\alpha$  and others, or Th2- cytokines such as IL-4, IL-5, IL10 among others.

iii) Measurement of cytokines: released from regional lymph nodes gives a good indication of successful immunization. As a result of antigen presentation and maturation of APC and immune effector cells such as CD4 and CD8 T cells, several cytokines are released by lymph node cells. By culturing these LNC *in vitro* in the presence of antigen, 20 antigen-specific immune response can be detected by measuring release of certain important cytokines such as IFN- $\gamma$ , IL-2, IL-12, TNF- $\alpha$  and GM-CSF. This could be done by ELISA using culture supernatants and recombinant cytokines as standards.

Successful immunization may be determined in a number of ways known to the skilled person including, but not limited to, hemagglutination inhibition (HAI) and 25 serum neutralization inhibition assays to detect functional antibodies; challenge studies, in which vaccinated subjects are challenged with the associated pathogen to determine the efficacy of the vaccination; and the use of fluorescence activated cell sorting (FACS) to determine the population of cells that express a specific cell surface marker, e.g. in the identification of activated or memory lymphocytes. A skilled person may also determine if 30 immunization with a composition of the invention elicited an antibody and/or cell mediated immune response using other known methods. See, for example, Current Protocols in Immunology Coligan et al., ed. (Wiley Interscience, 2007).

In further embodiments, the compositions of the invention may be administered to a subject to elicit and/or enhance an antibody and a cell mediated immune response to the antigen.

The invention finds broad application in the prevention and treatment of

5 any disease susceptible to prevention and/or treatment by way of administration of an antigen. Representative applications of the invention include cancer treatment and prevention, gene therapy, adjuvant therapy, infectious disease treatment and prevention, allergy treatment and prevention, autoimmune disease treatment and prevention, neuron-degenerative disease treatment, and atherosclerosis treatment, drug dependence

10 treatment and prevention, hormone control for disease treatment and prevention, control of a biological process for the purpose of contraception.

Prevention or treatment of disease includes obtaining beneficial or desired results, including clinical results. Beneficial or desired clinical results can include, but are not limited to, alleviation or amelioration of one or more symptoms or conditions,

15 diminishment of extent of disease, stabilisation of the state of disease, prevention of development of disease, prevention of spread of disease, delay or slowing of disease progression, delay or slowing of disease onset, conferring protective immunity against a disease-causing agent and amelioration or palliation of the disease state. Prevention or treatment can also mean prolonging survival of a patient beyond that expected in the

20 absence of treatment and can also mean inhibiting the progression of disease temporarily, although more preferably, it involves preventing the occurrence of disease such as by preventing infection in a subject.

The skilled artisan can determine suitable treatment regimes, routes of administration, dosages, etc., for any particular application in order to achieve the desired

25 result. Factors that may be taken into account include, e.g.: the nature of the antigen; the disease state to be prevented or treated; the age, physical condition, body weight, sex and diet of the subject; and other clinical factors. See, for example, "Vaccine Handbook", edited by the Researcher's Associates (Gaku-yuu-kai) of The National Institute of Health (1994); "Manual of Prophylactic Inoculation, 8th edition", edited by Mikio Kimura,

30 Munehiro Hirayama, and Harumi Sakai, Kindai Shuppan (2000); "Minimum Requirements for Biological Products", edited by the Association of Biologicals Manufacturers of Japan (1993).

Immune Responses

A composition of the invention may be used to induce an antibody response and/or cell-mediated immune response to the antigen that is formulated in the composition in a subject in need thereof. An immune response may be elicited and/or enhanced in a subject in need thereof to any antigen and/or to the cell that expresses it.

5 Thus, in embodiments of the invention, a composition may comprise an antigen derived from a bacteria, a virus, a fungus, a parasite, an allergen or a tumor cell, and may be formulated for use in the treatment and/or prevention of a disease caused by a bacteria, a virus, a fungus, a parasite, an allergen or a tumor cell, respectively.

10 A composition of the invention may be suitable for use in the treatment and/or prevention of cancer in a subject in need thereof. The subject may have cancer or may be at risk of developing cancer. Cancers that may be treated and/or prevented by the use or administration of a composition of the invention include, without limitation, carcinoma, adenocarcinoma, lymphoma, leukemia, sarcoma, blastoma, myeloma, and germ cell tumors. In one embodiment, the cancer may be caused by a pathogen, such as a virus. Viruses linked to the development of cancer are known to the skilled person and include, but are not limited to, human papillomaviruses (HPV), John Cunningham virus (JCV), Human herpes virus 8, Epstein Barr Virus (EBV), Merkel cell polyomavirus, Hepatitis C Virus and Human T cell leukaemia virus-1. A composition of the invention

15 may be used for either the treatment or prophylaxis of cancer, for example, in the reduction of the severity of cancer or the prevention of cancer recurrences. Cancers that may benefit from the compositions of the invention include any malignant cell that expresses one or more tumor specific antigen.

A composition of the invention may be suitable for use in the treatment and/or prevention of a viral infection in a subject in need thereof. The subject may be infected with a virus or may be at risk of developing a viral infection. Viral infections that may be treated and/or prevented by the use or administration of a composition of the invention include, without limitation, Cowpoxvirus, Vaccinia virus, Pseudocowpox virus, Human herpesvirus 1, Human herpesvirus 2, Cytomegalovirus, Human adenovirus A-F, Polyomavirus, Human papillomavirus, Parvovirus, Hepatitis A virus, Hepatitis B virus, Hepatitis C virus, Human immunodeficiency virus, Orthoreovirus, Rotavirus, Ebolavirus, parainfluenza virus, influenza A virus, influenza B virus, influenza C virus, Measles virus, Mumps virus, Rubella virus, Pneumovirus, Human respiratory syncytial virus, Rabies virus, California encephalitis virus, Japanese encephalitis virus, Hantaan virus,

Lymphocytic choriomeningitis virus, Coronavirus, Enterovirus, Rhinovirus, Poliovirus, Norovirus, Flavivirus, Dengue virus, West Nile virus, Yellow fever virus and varicella.

In one embodiment, a composition of the invention may be used to treat and/or prevent an influenza virus infection in a subject in need thereof. Influenza is a 5 single-stranded RNA virus of the family Orthomyxoviridae and is often characterized based on two large glycoproteins on the outside of the viral particle, hemagglutinin (HA) and neuraminidase (NA). Numerous HA subtypes of influenza A have been identified (Kawaoka et al., *Virology* (1990) 179:759-767; Webster et al., "Antigenic variation among type A influenza viruses," p. 127-168. In: P. Palese and D. W. Kingsbury (ed.), *Genetics 10 of influenza viruses*. Springer-Verlag, New York).

A composition of the invention may be suitable for use in the treatment and/or prevention of a neurodegenerative disease in a subject in need thereof, wherein the neurodegenerative disease is associated with the expression of an antigen. The subject may have a neurodegenerative disease or may be at risk of developing a 15 neurodegenerative disease. Neurodegenerative diseases that may be treated and/or prevented by the use or administration of a composition of the invention include, without limitation, Alzheimer's disease, Parkinson's disease, Huntington's disease, and amyotrophic lateral sclerosis (ALS).

In one embodiment, a composition of the invention may be used to treat and/or prevent Alzheimer's disease in a subject in need thereof. Alzheimer's disease is 20 characterized by the association of  $\beta$ -amyloid plaques and/or tau proteins in the brains of patients with Alzheimer's disease (see, for example, Goedert and Spillantini, *Science*, 314: 777-781, 2006). Herpes simplex virus type 1 has also been proposed to play a causative role in people carrying the susceptible versions of the apoE gene (Itzhaki and 25 Wozniak, *J Alzheimers Dis* 13: 393-405, 2008).

A subject administered or treated with a composition of the invention may result in the increase of an antibody and/or cell mediated immune response to the antigen relative to a subject treated with a control composition. As used herein, a "control 30 composition" may refer to any composition that does not contain at least one component of the claimed composition. Thus a control composition does not contain at least one of 1) an antigen, 2) liposome, 3) polyI:C or 4) a hydrophobic carrier. In one embodiment, a control composition does not contain polyI:C. In other embodiments, a control composition may contain alum instead of polyI:C.

A subject administered or treated with a composition of the invention may elicit an antibody immune response that is at least 1.50x, at least 1.75x, at least 2x, at least 2.5x, at least 3x, at least 3.5x, at least 4x, at least 4.5x, or at least 5x higher relative to a subject treated with a control composition. In one embodiment, the antibody titre 5 (expressed in terms of log10 value) from the serum of a subject treated with a composition of the invention is at least 0.05, at least 0.10, at least 0.15, at least 0.20, at least 0.25 or at least 0.30 higher than that of a subject treated with a control composition.

A subject administered or treated with a composition of the invention may elicit a cell mediated immune response that is at least 1.50x, at least 1.75x, at least 2x, at 10 least 2.5x, at least 3x, at least 3.5x, at least 4x, at least 4.5x, or at least 5x higher relative to a subject treated with a control composition.

A subject administered or treated with a composition of the invention may elicit a memory T cell population that is at least 1.50x, at least 1.75x, at least 2x, at least 2.5x, at least 3x, at least 3.5x, at least 4x, at least 4.5x, or at least 5x higher relative to a 15 subject treated with a control composition.

A subject administered or treated with a composition of the invention may prevent the development and/or delay the onset of a tumor in a subject, relative to a subject treated with a control composition.

The invention is further illustrated by the following non-limiting examples.

20

## EXAMPLE 1

Pathogen free, female CD1 mice, 6-8 weeks of age, were obtained from Charles River Laboratories (St Constant, QC, Canada) and were housed according to institutional guidelines with water and food ad libitum, under filter controlled air circulation.

The H5N1 recombinant hemagglutinin protein, was purchased from Protein 25 Sciences (Meridien, CT, USA). This recombinant protein has an approximate molecular weight of 72,000 daltons and corresponds to the hemagglutinin glycoprotein, an antigenic protein present on the surface of the H5N1 influenza virus. This recombinant protein, hereafter designated rHA, was used as a model antigen to test the efficacy of vaccine formulations. rHA was used at 1 microgram per 30 microliter dose.

30

Vaccine efficacy was assessed by enzyme-linked immunosorbent assay (ELISA), a method that allows the detection of antigen-specific antibody levels in the

serum of immunized animals. Performing the ELISA on sera collected from immunized mice on a regular interval (every four weeks for example), is useful for monitoring the antibody responses to a given vaccine formulation. Briefly, a 96-well microtiter plate is coated with antigen (rHA, 1 microgram/ milliliter) overnight at 4 degrees Celsius, blocked 5 with 3% gelatin for 30 minutes, then incubated overnight at 4 degrees Celsius with serial dilutions of sera, typically starting at a dilution of 1/2000. A secondary reagent (protein G conjugated to alkaline phosphatase, EMD chemicals, Gibbstown, NJ, USA) is then added to each well at a 1/500 dilution for one hour at 37 degrees Celsius. Following a 60 minute incubation with a solution containing 1 milligram/ milliliter 4-nitrophenyl phosphate 10 disodium salt hexahydrate (Sigma-Aldrich Chemie GmbH, Switzerland), the 405 nanometer absorbance of each well is measured using a microtiter plate reader (ASYS Hitech GmbH, Austria). Endpoint titers are calculated as described in Frey A. et al (Journal of Immunological Methods, 1998, 221:35-41). Calculated titers represent the highest dilution at which a statistically significant increase in absorbance is observed in 15 serum samples from immunized mice versus serum samples from naïve, non-immunized control mice. Titers are presented as log<sub>10</sub> values of the endpoint dilution.

To formulate vaccine described herein, a 10:1 w:w homogenous mixture of S100 lecithin and cholesterol (Lipoid GmbH, Germany) was hydrated in the presence of a rHA solution in phosphate buffered saline (pH 7.4) to form liposomes with encapsulated 20 rHA. In brief, 33 micrograms of rHA were first suspended in 300 microliters of phosphate buffered saline (pH 7.4) then added to 132 milligrams of the S100 lecithin/ cholesterol mixture to form approximately 450 microliters of a liposome suspension encapsulating the rHA antigen. The liposome preparation was extruded by passing the material through a manual mini-extruder (Avanti, Alabaster, AL, USA) fitted with a 200 nanometer 25 polycarbonate membrane. For every 450 microliters of liposome suspension containing rHA, two milligrams of Imject Alum adjuvant (Pierce, Rockford, IL, USA) was added. For every 500 microliters of a liposome/ antigen/ adjuvant suspension, an equal volume of a mineral oil carrier equivalent to Freund's incomplete adjuvant (known as Montanide(TM) ISA 51, supplied by Seppic, France) was added to form a water-in-oil emulsion with the 30 liposome suspension contained within the water phase of the emulsion and the oil forming a continuous hydrophobic phase. Each vaccine dose consisted of 30 microliters of the above-described emulsion containing liposomes, rHA antigen, alum adjuvant, and the mineral oil carrier. This vaccine formulation will be referred to as liposome/ alum/ hydrophobic carrier.

To formulate the vaccine corresponding to the invention, the same procedures described above were used with the following exception: following the formation of liposomes encapsulating rHA, and after extruding the liposome suspension through a 200 nanometer polycarbonate membrane, 133 micrograms of polyI:C adjuvant (Pierce, Rockford, IL, USA) were added to every 450 microliters of liposomes. For every 500 microliters of a liposome/ antigen/ adjuvant suspension, an equal volume of a mineral oil carrier (Montanide(TM) ISA 51, Seppic, France) was added to form a water-in-oil emulsion with the liposome suspension contained in the water phase of the emulsion and the oil forming the continuous phase. Each vaccine dose consisted of 30 microliters of the above described emulsion containing liposomes, rHA antigen, polyI:C adjuvant, and the mineral oil carrier. This particular formulation will be referred to as liposome/ polyI:C/ hydrophobic carrier.

The efficacy of the two emulsion formulations described above was compared to the efficacy of a control vaccine consisting of 1 microgram of rHA and 60 micrograms of alum adjuvant in 30 microliters of phosphate buffered saline (pH 7.4). Two groups of mice (9 or 10 mice per group) were injected once (no boosting) with liposome vaccine formulations, intramuscularly, as follows: Group 1 mice were vaccinated with Vaccine B comprising 1 microgram of rHA antigen formulated in 30 microliters of liposome/ polyI:C/ hydrophobic carrier as described above. Each vaccine dose effectively contained 4 micrograms of polyI:C. Group 2 mice were vaccinated with Vaccine A comprising 1 microgram of rHA formulated in 30 microliters of liposome/ alum/ hydrophobic carrier as described above. Each vaccine dose effectively contained 60 micrograms of alum. The control group of mice (Group 3, n=10) was injected intramuscularly with the control alum vaccine consisting of 1 microgram of rHA and 60 micrograms of alum suspended in phosphate buffered saline. Serum samples were collected from all mice at 18 days and 28 days post-immunization. Antibody titers in these sera were examined by ELISA as described above.

Group 3 mice generated a detectable antigen-specific antibody response as was expected following the administration of an alum-adjuvanted control vaccine. Not surprisingly, Group 2 mice vaccinated with a liposome/ alum/ hydrophobic carrier formulation generated a considerably higher antibody response. While these results were expected, the use of polyI:C adjuvant instead of alum adjuvant in a liposome/ polyI:C/ hydrophobic carrier formulation (Group 1 mice), yielded some unexpected result; antibody titers were significantly higher than those generated by the liposome/ alum/ hydrophobic carrier formulation (Group 2).

Group 3 mice, vaccinated with the aqueous control formulation described above, generated endpoint titers up to 1/32,000 and 1/64,000 at 18 and 28 days post-vaccination (log10 values of 4.51 and 4.81 respectively). The endpoint titers at 18 and 28 days post-vaccination in Group 2 were up to 1/256,000 (log10 value of 5.41). The

5 presence of such antibody responses at 18 and 28 days (4 weeks) post-vaccination confirms that a genuine immune response was generated as a result of vaccination.

Group 1 mice that were injected with the formulation corresponding to the invention were able to generate an enhanced immune response with endpoint titers reaching up to 1/1,024,000 (log10 value of 6.01) at 18 days post-vaccination and 1/8,192,000 (a log10

10 value of 6.91) at four weeks post-immunization. These results indicate that liposome/ hydrophobic carrier formulations containing a polyI:C adjuvant are capable of generating a significantly enhanced *in vivo* immune response compared to liposome/ alum/ hydrophobic carrier and aqueous/ alum control vaccinations.

## EXAMPLE 2

15 Pathogen free, female CD1 mice, 6-8 weeks of age, were obtained from Charles River Laboratories (St Constant, QC, Canada) and were housed according to institutional guidelines with water and food ad libitum, under filter controlled air circulation.

As in example 1, H5N1 recombinant hemagglutinin protein, corresponding to the hemagglutinin glycoprotein on the surface of the H5N1 influenza virus, was 20 purchased from Protein Sciences (Meridien, CT, USA). This recombinant protein, hereafter designated rHA, was used as a model antigen to test the efficacy of vaccine formulations. rHA was used at 1 microgram per 30 microliter dose.

To formulate the vaccine corresponding to the invention, the same procedures as described in example one were used. In summary, 33 micrograms of rHA 25 were suspended in 300 microliters of phosphate buffered saline (pH 7.4) then added to 132 milligrams of a S100 lecithin/ cholesterol mixture (Lipoid GmbH, Germany) to form approximately 450 microliters of a liposome suspension encapsulating the rHA antigen. The liposome preparation was extruded by passing the material through a manual mini-extruder (Avanti, Alabaster, AL, USA) fitted with a 200 nanometer polycarbonate 30 membrane. For every 450 microliters of liposome suspension containing rHA, 133 micrograms of polyI:C adjuvant (Pierce, Rockford, IL, USA) was added. For every 500 microliters of a liposome/ antigen/ adjuvant suspension, an equal volume of a mineral oil carrier (Montanide(TM) ISA 51, Seppic, France) was added to form a water-in-oil

emulsion with the liposome suspension contained within the water phase of the emulsion and the oil forming a continuous hydrophobic phase. Each vaccine dose consisted of 30 microliters of the above described emulsion containing liposomes, rHA antigen, polyI:C adjuvant, and the mineral oil carrier. This particular formulation will be referred to as 5 liposome/ polyI:C/ hydrophobic carrier.

The efficacy of the liposome/ polyI:C/ hydrophobic carrier vaccine described above was compared to the efficacy of an aqueous control vaccine containing polyI:C adjuvant. Two groups of mice (9 or 10 mice per group) were injected once, intramuscularly, with 30 microliters per dose. Group 1 mice were vaccinated with Vaccine 10 B comprising 1 microgram of rHA and 4 micrograms of polyI:C formulated in 30 microliters of liposome/ polyI:C/ hydrophobic carrier as described above. Group 2 mice were injected with 30 microliters of the control polyI:C vaccine comprising 1 microgram rHA and 4 micrograms polyI:C formulated in phosphate buffered saline (pH 7.4). Serum samples were collected from all mice at 18 and 28 days post-immunization. rHA antibody titers of 15 the sera samples were examined by ELISA as described in example 1.

Group 2 mice generated a detectable antigen-specific antibody response following the administration of a polyI:C-adjuvanted control vaccine. Group 1 mice, vaccinated with the liposome/ polyI:C/ hydrophobic carrier formulation, yielded significantly enhanced endpoint titers compared to those of Group 2. Group 2 mice 20 generated titers up to 1/128,000 (log10 value of 5.11) at 18 days post-vaccination and up to 1/1,024,000 (log10 equal to 6.01) at 28 days (4 weeks) post-vaccination. As noted in example 1, the presence of such antibody responses confirms a genuine immune response generated as a result of the vaccination. Group 1 mice, vaccinated with the vaccine corresponding to the invention, were able to generate endpoint titers reaching up 25 to 1/1,024,000 (log10 value of 6.01) at 18 days post-vaccination and 1/8,192,000 (a log10 value of 6.91) at four weeks post-immunization. These results indicate that liposome/ hydrophobic carrier formulations containing a polyI:C adjuvant are capable of generating a significantly enhanced *in vivo* immune response compared to an aqueous/ polyI:C control vaccination.

30

### EXAMPLE 3

Pathogen free, female CD1 mice, 6-8 weeks of age, were obtained from Charles River Laboratories (St Constant, QC, Canada) and were housed according to institutional guidelines with water and food ad libitum, under filter controlled air circulation.

As in examples 1 and 2, H5N1 recombinant hemagglutinin protein, corresponding to the hemagglutinin glycoprotein on the surface of the H5N1 influenza virus, was purchased from Protein Sciences (Meridien, CT, USA). This recombinant protein, hereafter designated rHA, was used as a model antigen to test the efficacy of 5 vaccine formulations. rHA was used at 1 microgram per 50 microliter dose.

To formulate vaccine corresponding to the invention, a 10:1 w:w homogenous mixture of S100 lecithin and cholesterol (Lipoid GmbH, Germany) was hydrated in the presence of a rHA and polyI:C adjuvant (Pierce, Rockford, IL, USA) solution in phosphate buffer to form liposomes with encapsulated rHA and adjuvant. In 10 brief, 20 micrograms of rHA and 200 micrograms polyI:C were first suspended in 250 microliters of 50 millimolar phosphate buffer (pH 7.4) then added to 132 milligrams of the S100 lecithin/ cholesterol mixture to form approximately 400 microliters of a liposome suspension encapsulating the rHA antigen and polyI:C adjuvant. The liposome preparation was diluted in half using 50 millimolar phosphate buffer (pH 7.4) and then 15 extruded by passing the material through a manual mini-extruder (Avanti, Alabaster, AL, USA) fitted with a 200 nanometer polycarbonate membrane. Sized liposomes were then lyophilized using the Virtis Advantage freeze dryer (SP Industries, Warminster, PA, USA). For every 800 microliters of original liposome suspension containing rHA and polyI:C, one 20 milliliter of a mineral oil carrier equivalent to Freund's incomplete adjuvant (known as Montanide(TM) ISA 51, supplied by Seppic, France) was used to reconstitute the lyophilized liposomes. Each vaccine dose consisted of 50 microliters of the above described formulation combining liposomes, rHA antigen, polyI:C adjuvant, and the mineral oil carrier. This vaccine formulation will be referred to as lyophilized liposome/polyI:C/ hydrophobic carrier.

25 The efficacy of the lyophilized liposome formulation described above was compared to the efficacy of a control vaccine consisting of 1 microgram of rHA and 100 micrograms of Imject Alum adjuvant (Pierce, Rockford, IL, USA) in 50 microliters of 30 50 millimolar phosphate buffer (pH 7.4). Group 1 mice (N = 8) were injected once (no boosting) with Vaccine C comprising 1 microgram of rHA antigen and 10 micrograms of polyI:C adjuvant formulated in 50 microliters of lyophilized liposome/ polyI:C/ hydrophobic carrier as described above. Group 2 mice (N = 9) were vaccinated twice (day 0 and day 21) with the control alum vaccine comprising 1 microgram of rHA and 100 micrograms of alum adjuvant suspended in 50 millimolar phosphate buffer. Serum samples were 35 collected from all mice at 3, 4, and 8 weeks post-immunization. rHA antibody titers in these sera were examined by ELISA as described in example 1.

Group 2 mice generated a detectable antigen-specific antibody response following the administration of an alum-adjuvanted control vaccine. Group 1 mice, vaccinated with a single dose of the lyophilized liposome/ polyI:C/ hydrophobic carrier formulation, yielded significantly enhanced endpoint titers compared to those of Group 2, despite that Group 2 animals were vaccinated twice (primary immunization plus boost). Group 2 mice generated titers up to 1/128,000 (log10 value of 5.11) at three weeks post-vaccination (before boost) and up to 1/1,024,000 (log10 equal to 6.01) and 1/512,000 (log10 equal to 5.71) at four and eight weeks respectively (after boost). As noted in example 1, the presence of such antibody responses confirms a genuine immune response generated as a result of the vaccination. Group 1 mice, vaccinated with the vaccine corresponding to the invention, were able to generate endpoint titers reaching up to 1/2,048,000 (log10 value of 6.31) at three weeks post-vaccination and 1/8,192,000 (a log10 value of 6.91) at four and eight weeks post-immunization. These results indicate that single dose lyophilized liposome/ hydrophobic carrier formulations containing a polyI:C adjuvant are capable of generating a significantly enhanced *in vivo* immune response compared to a boosted, aqueous alum control vaccination. The immune responses generated in this example are equivalent to the immune responses generated by a vaccine of the invention presented in Examples 1 and 2.

#### EXAMPLE 4

Pathogen free, female CD1 mice, 6-8 weeks of age, were obtained from Charles River Laboratories (St Constant, QC, Canada) and were housed according to institutional guidelines with water and food ad libitum, under filter controlled air circulation.

As in the previous examples, H5N1 recombinant hemagglutinin protein (Protein Sciences, Meridien, CT, USA) corresponding to the hemagglutinin glycoprotein present on the surface of the H5N1 influenza virus, hereafter designated rHA, was used as a model antigen to test the efficacy of vaccine formulations. rHA was used at 1 microgram per 30 microliter dose.

Vaccines described herein were formulated as described in Example 1. Briefly, 33 micrograms of rHA were suspended in 300 microliters of phosphate buffered saline (pH 7.4) then added to 132 milligrams of a homogeneous (10:1, w:w) S100 lecithin/ cholesterol mixture (Lipoid GmbH, Germany) to form approximately 450 microliters of a liposome suspension encapsulating the rHA antigen. The liposome preparation was extruded by passing the material through a manual mini-extruder (Avanti, Alabaster, AL,

USA) fitted with a 200 nanometer polycarbonate membrane. For every 450 microliters of liposome suspension containing rHA, two milligrams of Imject Alum adjuvant (Pierce, Rockford, IL, USA) was added. For every 500 microliters of a liposome/ antigen/ adjuvant suspension, an equal volume of a mineral oil carrier (Montanide(TM) ISA 51, supplied by 5 Seppic, France) was added to form a water-in-oil emulsion with the liposome suspension contained within the water phase of the emulsion and the oil forming a continuous hydrophobic phase. Each vaccine dose consisted of 30 microliters of the above described emulsion containing liposomes, rHA antigen, alum adjuvant, and the mineral oil carrier. This vaccine formulation will be referred to as liposome/ alum/ hydrophobic 10 carrier.

To formulate the vaccine corresponding to the invention, the same procedures as described above were used with the following exception: following the formation of liposomes encapsulating rHA, and after extruding the liposome suspension through a 200 nanometer polycarbonate membrane, 133 micrograms of RNA-based 15 polyI:C adjuvant (Pierce, Rockford, IL, USA) were added to every 450 microliters of liposomes. For every 500 microliters of a liposome/ antigen/ adjuvant suspension, an equal volume of a mineral oil carrier (Montanide(TM) ISA 51, Seppic, France) was added to form a water-in-oil emulsion with the liposome suspension contained in the water phase of the emulsion and the oil forming the continuous phase. Each vaccine dose consisted 20 of 30 microliters of the above described emulsion containing liposomes, rHA antigen, polyI:C adjuvant, and the mineral oil carrier. This particular formulation will be referred to as liposome/ polyI:C/ hydrophobic carrier.

The efficacy of the two emulsion formulations described above was compared as described in Example 1. Two groups of mice (9 or 10 mice per group) were 25 injected once (no boosting) with liposome vaccine formulations, intramuscularly, as follows: Group 1 mice were vaccinated with Vaccine B comprising 1 microgram of rHA antigen and 4 micrograms of polyI:C adjuvant formulated in 30 microliters of liposome/ polyI:C/ hydrophobic carrier (the invention). Group 2 mice were vaccinated with 1 microgram of rHA and 60 micrograms of alum adjuvant formulated in 30 microliters of 30 liposome/ alum/ hydrophobic carrier. Group 2 vaccine was a control formulation (Vaccine A) containing the generic adjuvant alum. Serum samples were collected from all mice at 18 and 28 days post-immunization and then every four weeks for a total of 16 weeks. Antibody titers in these sera were examined by ELISA as described in Example 1.

The endpoint titers in Group 2 were up to 1/256,000 at 8 and 12 weeks and 1/512,000 at 16 weeks post-immunization (log10 values of 5.41 and 5.71 respectively).

Group 1 mice that were injected with the formulation corresponding to the invention were able to generate an enhanced immune response with endpoint titers reaching up to

5 1/4,096,000 (log10 value of 6.61) at 8, 12 and 16 weeks post-vaccination. These results confirm that liposome/ hydrophobic carrier formulations containing a polyI:C adjuvant are capable of generating a significantly enhanced *in vivo* immune response that is on average 10 times greater than what is achieved using a control vaccine lacking polyI:C (P values < than 0.01 at all time points between weeks 4 and 16 post-vaccination). The 10 dramatic improvement in the immune response generated was a result of using the polyI:C adjuvant specifically instead of alum in the antigen/ liposome/ adjuvant/ mineral oil carrier composition. The stronger immune response generated with the vaccine of this invention was robust, as it persisted at significantly superior levels compared to the alum containing vaccine for a minimum of 16 weeks.

15

## EXAMPLE 5

Pathogen free, female CD1 mice, 6-8 weeks of age, were obtained from Charles River Laboratories (St Constant, QC, Canada) and were housed according to institutional guidelines with water and food ad libitum, under filter controlled air circulation.

As in the previous examples, H5N1 recombinant hemagglutinin protein, 20 corresponding to the hemagglutinin glycoprotein on the surface of the H5N1 influenza virus, was purchased from Protein Sciences (Meridien, CT, USA). This recombinant protein, hereafter designated rHA, was used as a model antigen to test the efficacy of vaccine formulations. rHA was used at 1 microgram per 30 microliter dose.

To formulate the vaccine corresponding to the invention, the same 25 procedures as described in Example 2 were used. In summary, 33 micrograms of rHA were suspended in 300 microliters of phosphate buffered saline (pH 7.4) then added to 132 milligrams of a S100 lecithin/ cholesterol mixture (Lipoid GmbH, Germany) to form approximately 450 microliters of a liposome suspension encapsulating the rHA antigen. The liposome preparation was extruded by passing the material through a 200 nanometer 30 polycarbonate membrane. For every 450 microliters of liposome suspension containing rHA, 133 micrograms of RNA-based polyI:C adjuvant (Pierce, Rockford, IL, USA) was added. For every 500 microliters of a liposome/ antigen/ adjuvant suspension, an equal volume of a mineral oil carrier (Montanide(TM) ISA 51, Seppic, France) was added to

form a water-in-oil emulsion with the liposome suspension contained within the water phase of the emulsion and the oil forming the continuous phase. Each vaccine dose consisted of 30 microliters of the above described emulsion containing liposomes, rHA antigen, polyI:C adjuvant, and the mineral oil carrier. This particular formulation will be  
5 referred to as liposome/ polyI:C/ hydrophobic carrier.

The efficacy of the liposome/ polyI:C/ hydrophobic carrier vaccine described above was compared to the efficacy of an aqueous control vaccine containing rHA antigen and RNA-based polyI:C adjuvant. Two groups of mice (9 or 10 mice per group) were injected once, intramuscularly, with 30 microliters per dose. Group 1 mice  
10 were vaccinated with Vaccine B comprising 1 microgram of rHA and 4 micrograms of polyI:C formulated as liposome/ polyI:C/ hydrophobic carrier as described above. Group 2 mice were injected with the control polyI:C vaccine comprising 1 microgram rHA and 4 micrograms polyI:C formulated in phosphate buffered saline (pH 7.4). Serum samples were collected from all mice at 18 and 28 days post-immunization and then  
15 every four weeks for a total of 16 weeks. rHA antibody titers of the sera samples were examined by ELISA as described in Example 1.

Group 2 mice generated a detectable, antigen-specific antibody response following the administration of a polyI:C-adjuvanted control vaccine. Group 1 mice, vaccinated with the liposome/ polyI:C/ hydrophobic carrier formulation, yielded  
20 significantly enhanced endpoint titers compared to those of Group 2. Group 2 mice generated titers up to 1/512,000 (log10 value of 5.71) at 8 weeks and up to 1/2,048,000 (log10 equal to 6.31) at 12 and 16 weeks post-vaccination. As noted previously, the presence of such antibody responses confirms a genuine immune response generated as a result of the vaccination. Group 1 mice, vaccinated with the vaccine corresponding to  
25 the invention, were able to generate endpoint titers reaching up to 1/4,096,000 (log10 value of 6.61) at 8, 12 and 16 weeks post-immunization. These results confirm that liposome/ hydrophobic carrier formulations containing a polyI:C adjuvant are capable of generating a durable and substantially higher *in vivo* immune response compared to an aqueous/ polyI:C control vaccination (P value < 0.02 at week 4 and week 16 post-  
30 vaccination). Antibody titers that were 7 times higher on average at early (week 4 post vaccination) and 9 times higher on average at late (week 16 post-vaccination) time points were achieved in the presence of liposomes and a hydrophobic carrier in the vaccine. This suggests that the liposome and hydrophobic carrier components are important for generating the strong immune responses observed.

## EXAMPLE 6

Pathogen free, female BALB/c mice, 6-8 weeks of age, were obtained from Charles River Laboratories (St Constant, QC, Canada) and were housed according to institutional guidelines with water and food ad libitum, under filter controlled air circulation.

5 As in Examples 1 through 5, H5N1 recombinant hemagglutinin protein, corresponding to the hemagglutinin glycoprotein on the surface of the H5N1 influenza virus, was purchased from Protein Sciences (Meridien, CT, USA). This recombinant protein, hereafter designated rHA, was used as a model antigen to test the efficacy of vaccine formulations. rHA was used at 1.5 micrograms per 50 microliter dose.

10 To formulate vaccine corresponding to the invention, a 10:1 (w:w) homogenous mixture of S100 lecithin and cholesterol (Lipoid GmbH, Germany) was hydrated in the presence of rHA in phosphate buffer to form liposomes with encapsulated rHA and followed by the addition of polyI:C (Pierce, Rockford, IL, USA). In brief, 30 micrograms of rHA were suspended in 750 microliters of 50 millimolar phosphate buffer 15 (pH 7.0) then added to 132 milligrams of the S100 lecithin/ cholesterol mixture to form approximately 900 microliters of a liposome suspension encapsulating the rHA antigen. The liposome preparation was extruded by passing the material through a semi-automatic extruder (Avestin, Ottawa, ON, Canada) fitted with a 200 nanometer polycarbonate membrane at a flow rate of 100 milliliters per minute. 250 micrograms of RNA- based 20 polyI:C adjuvant in 50 millimolar phosphate buffer (pH 7.0) was added to sized liposomes to dilute the preparation to 1 milliliter. Liposomes were then lyophilized using the Virtis Advantage freeze dryer (SP Industries, Warminster, PA, USA). For every 1 milliliter of original liposome suspension containing rHA and polyI:C, 800 microliters of a mineral oil carrier (Montanide(TM) ISA 51, Seppic, France) was used to reconstitute the lyophilized 25 liposomes. Each vaccine dose consisted of 50 microliters of the above described formulation containing liposomes, rHA antigen, polyI:C adjuvant, and the mineral oil carrier. This vaccine formulation will be referred to as lyophilized liposome/ polyI:C/ hydrophobic carrier.

30 The efficacy of the lyophilized liposome formulation described above was compared to the efficacy of a control vaccine consisting of 1.5 micrograms of rHA and 100 micrograms of Imject Alum adjuvant (Pierce, Rockford, IL, USA) in 50 microliters of 50 millimolar phosphate buffer (pH 7.0). Group 1 mice (N = 10) were injected intramuscularly, once (no boosting), with Vaccine D comprising 1.5 micrograms of rHA

antigen and 12.5 micrograms of RNA-based polyI:C adjuvant formulated in 50 microliters of lyophilized liposome/ polyI:C/ hydrophobic carrier as described above. Group 2 mice (N=10 at weeks 3 and 4 reduced to N=9 at weeks 6 and 9 due to unplanned non-vaccine related termination of one animal) were vaccinated twice (day 0 and day 28) with a control 5 alum vaccine comprising 1.5 micrograms of rHA and 100 micrograms of alum adjuvant suspended in 50 millimolar phosphate buffer. Serum samples were collected from all mice at 3, 4, 6 and 9 weeks post-immunization. rHA antibody titers in these sera were examined by ELISA as described in Example 1.

Group 2 mice generated an antigen-specific antibody response only after 10 the administration of 2 doses (primary immunization and boost) of an alum-adjuvanted control vaccine. Group 1 mice, vaccinated with a single dose of the lyophilized liposome/ polyI:C/ hydrophobic carrier formulation, yielded significantly enhanced endpoint titers compared to those of Group 2 at all time points tested despite that Group 2 animals were vaccinated twice. Group 2 mice recorded background titers 3 weeks after the primary 15 vaccination and one individual generated a maximum titer of 1/8,000 (log<sub>10</sub> equal to 3.39) at 4 weeks. After the boost, Group 2 mice generated titers up to 1/64,000 (log<sub>10</sub> value of 4.81) at 6 and 9 weeks post-immunization. Group 1 mice, vaccinated with the vaccine corresponding to the invention, were able to generate endpoint titers up to 1/128,000 20 (log<sub>10</sub> of 5.11) at 3 and 4 weeks post-vaccination and 1/512,000 (a log<sub>10</sub> value of 5.71) at 6 and 9 weeks post-immunization. These results confirm, using a different mouse 25 species than the one used in Example 3, that a single dose of lyophilized liposome/ hydrophobic carrier formulations containing a polyI:C adjuvant is capable of generating a significantly enhanced *in vivo* humoral immune response compared to even a boosted, aqueous/ alum control vaccination. Antibody levels were 24 times higher than a single dose of the control vaccine at week 4 post-vaccination (P value < 0.001) and 9 times higher than two doses of the control vaccine at the later time point of 9 weeks post-vaccination (P value < 0.01). Furthermore, results from Examples 3 and 6 indicate that the polyI:C adjuvant can be incorporated into the lyophilized liposome/ hydrophobic carrier formulation either before or after liposome extrusion.

Pathogen free, female BALB/c mice, 6-8 weeks of age, were obtained from Charles River Laboratories (St Constant, QC, Canada) and were housed according to institutional guidelines with water and food ad libitum, under filter controlled air circulation.

As in Examples 1 through 6, H5N1 recombinant hemagglutinin protein, corresponding to the hemagglutinin glycoprotein on the surface of the H5N1 influenza virus, was purchased from Protein Sciences (Meridien, CT, USA). This recombinant protein, hereafter designated rHA, was used as a model antigen to test the efficacy of 5 vaccine formulations. rHA was used at 1.5 micrograms per 50 microliter dose.

In this example, the lyophilized liposome/ polyI:C/ hydrophobic carrier was administered intramuscularly once (no boosting) or subcutaneously once (no boosting) to evaluate the generation of antigen-specific cytotoxic lymphocyte response.

To formulate the vaccine corresponding to the invention, the same 10 procedures as described in Example 6 were used. In summary, liposomes were formulated by hydrating a 10:1 (w:w) homogeneous mixture of S100 lecithin and cholesterol (Lipoid GmbH, Germany) in the presence of rHA in phosphate buffer followed by the addition of RNA-based polyI:C (Pierce, Rockford, IL, USA). The liposome suspension was lyophilized and resuspended in a mineral oil carrier (Montanide ISA 15 51(TM), SEPPIC, France). Each vaccine dose (Vaccine D) consisted of 50 microliters of the above described formulation containing liposomes (6.6 mg of S100/cholesterol lipids), rHA antigen (1.5 micrograms), polyI:C adjuvant (12.5 micrograms), and the mineral oil carrier. This vaccine formulation will be referred to as lyophilized liposome/ polyI:C/ hydrophobic carrier. Mice in Group 1 (n=4) received this formulation intramuscularly as in 20 Example 6. Group 2 mice (n=4) received this vaccine subcutaneously.

Mice in Group 3 (n=4) were vaccinated with the control alum vaccine consisting of 1.5 micrograms of rHA and 100 micrograms of Imject Alum adjuvant (Pierce, Rockford, IL, USA) in 50 microliters of 50 millimolar phosphate buffer (pH 7.0). Mice were injected intramuscularly once (no boost). Group 4 mice (n=2) were naïve and did not 25 receive any immunization.

Twenty-two days after vaccination, animals were euthanized by carbon dioxide induced asphyxiation. The spleens were collected and individual single cell suspensions prepared using standard procedures. Red blood cells were lysed using ACK lysis buffer (0.15 M NH4Cl, 10 mM KHC03, 0.1 mM Na2EDTA in distilled H20). To 30 augment the antigen specific T cells, splenocytes were cultured at 1x10<sup>6</sup> cells per millilitre in RPMI 1640 (Invitrogen, Burlington, ON, Canada) complete media containing 1% Penicillin/ Streptomycin/ Glutamine, 0.1% 2-mercaptoethanol (Sigma-Aldrich, St. Louis, MO, USA), and 10% fetal bovine serum (Hyclone, Logan, UT, USA) supplemented

with 20 units per millilitre of recombinant human IL-2 (Sigma-Aldrich) and 10 micrograms per millilitre rHA for 4 days at 37°C, 5% carbon dioxide. Tri-colour flow cytometric analysis was performed on splenocytes to detect antigen-specific CD8+ T cells. Cells were blocked with a 10 minute treatment at room temperature of FC-block (eBioscience, 5 San Diego, CA, USA). Cells were then stained with phycoerythrin (PE)-labeled IYSTVASSL (I9L)/H2-Kd pentamer obtained from Proimmune (Bradenton, FL, USA) for 20 minutes at 4°C. I9L is the H2-Kd immunodominant epitope of rHA (518-528), and the pentamer reagent detects MHC I presentation of this epitope by the mouse. Cells were then stained with anti-CD19-fluorescein isothiocyanate (FITC) (eBioscience) and anti- 10 CD8β- Allophycocyanin (APC) (eBioscience) for 30 minutes at 4°C protected from light, washed and fixed in 50 millimolar phosphate buffer (pH 7.0) with 0.1% paraformaldehyde. 5×10<sup>5</sup> cells were acquired on a FACSCalibur(TM) flow cytometer (BD Bioscience, 15 Missisauga, ON, Canada) and analysed using WinList 6.0 software (Verity Inc, Topsham, ME, USA). Results were gated based on forward and side scatter, and antigen-specific 15 CD8 T cells were defined as pentamer positive, CD8β positive and CD19 negative. Statistical analysis was performed using two-tailed Students' T test.

Mice vaccinated with the control alum-based formulation generated a small population of antigen-specific CD8 T cells (0.045%). Mice vaccinated with the lyophilized liposome/ polyI:C/ hydrophobic carrier formulation of the present invention, delivered by 20 the intramuscular or subcutaneous route, generated a significantly higher population of antigen-specific CD8 T cells (0.23% and 0.17% respectively; p=<0.025 for both compared to alum control). These results demonstrate that rHA formulated in the invention can be delivered intramuscularly or subcutaneously and generate a significantly higher antigen-specific CD8+ T cell population representative of a cellular immune response compared 25 to a conventional vaccine formulation using alum.

#### EXAMPLE 8

Pathogen free, female CD-1 mice, 6-8 weeks of age, and female New Zealand White rabbits, 2-3 kilograms in weight, were obtained from Charles River Laboratories (St Constant, QC, Canada) and were housed according to institutional 30 guidelines with water and food ad libitum, under filtered air circulation.

As in Examples 1 through 7, H5N1 recombinant hemagglutinin protein, corresponding to the hemagglutinin glycoprotein on the surface of the H5N1 influenza virus, was purchased from Protein Sciences (Meridien, CT, USA). This recombinant

protein, hereafter designated rHA, was used as a model antigen to test the efficacy of vaccine formulations. rHA was used at 0.5 micrograms per 50 microliter dose in mice and 2 micrograms per 200 microliter dose in rabbits.

Vaccine efficacy was assessed by hemagglutination inhibition assays (HAI) 5 conducted by Benchmark Biolabs (Lincoln, NE, USA). Briefly, serum samples were pre-treated with a receptor destroying enzyme and pre-absorbed to chicken red blood cells to avoid any non-specific hemagglutination inhibition reactions. Serial dilutions of sera were then incubated with 0.7% equine red blood cells, 0.5% bovine serum albumin and 8 HA units of A/Vietnam/1203/2004[H5N1] influenza virus. Calculated titers represent the 10 highest dilution at which the serum sample can completely inhibit hemagglutination of the red blood cells.

To formulate the first vaccine corresponding to the invention, a 10:1 (w:w) homogenous mixture of S100 lecithin and cholesterol (Lipoid GmbH, Germany) was hydrated in the presence of rHA in phosphate buffer to form liposomes with encapsulated 15 rHA and followed by the addition of RNA-based polyI:C (Pierce, Rockford, IL, USA). Briefly, 10 micrograms of rHA were first suspended in 650 microliters of 50 millimolar phosphate buffer (pH 7.0) then added to 132 milligrams of the S100 lecithin/ cholesterol mixture to form approximately 800 microliters of a liposome suspension encapsulating the rHA antigen. The liposome preparation was then extruded by passing the material 20 through a manual mini-extruder (Avanti, Alabaster, AL, USA) fitted with a 200 nanometer polycarbonate membrane. 240 micrograms of polyI:C adjuvant in 50 millimolar phosphate buffer (pH 7.0) were added to sized liposomes. Liposomes were then lyophilized using the Virtis Advantage freeze dryer (SP Industries, Warminster, PA, USA). The lyophilized material was reconstituted with a mineral oil carrier (Montanide(TM) ISA 51, supplied by 25 Seppic, France) up to the original 1 milliliter volume of solubilized liposomes. Each vaccine dose as delivered to mice, consisted of 50 microliters of the above described formulation combining liposomes, rHA antigen, polyI:C adjuvant, and the mineral oil carrier. These vaccine formulations will be referred to as lyophilized liposome/ polyI:C/ hydrophobic carrier.

30 To formulate the second vaccine, also corresponding to the invention, the same procedures described above were used with the following exceptions: following the formation of liposomes encapsulating rHA antigen, the liposome preparation was extruded by passing the material through a manual mini-extruder fitted with two 400 nanometer polycarbonate membranes. 250 micrograms of the RNA-based polyI:C

adjuvant in 50 millimolar phosphate buffer (pH 7.0) was added to sized liposomes to dilute the preparation to 1 milliliter. Liposomes were then lyophilized using the Virtis Advantage freeze dryer and the lyophilized material reconstituted to the original 1 milliliter using a mineral oil carrier (Montanide(TM) ISA 51, Seppic, France). Each vaccine dose delivered 5 to rabbits consisted of 200 microliters of the above described formulation containing liposomes, rHA antigen, polyI:C adjuvant, and the mineral oil carrier. This vaccine formulation will also be referred to as lyophilized liposome/ polyI:C/ hydrophobic carrier.

The efficacy of the lyophilized liposome formulations described above was tested using two different animal models. Animals were vaccinated with comparable 10 formulations; the injection volume was adjusted as appropriate for the size of the animals. One group of mice (N=5) were injected intramuscularly with Vaccine F comprising 0.5 micrograms of rHA antigen and 12 micrograms of polyI:C adjuvant formulated in 50 microliters of lyophilized liposome/ polyI:C/ hydrophobic carrier as described above. One group of rabbits (N=5) were injected subcutaneously with Vaccine E comprising 2 15 micrograms of rHA antigen and 50 micrograms of polyI:C adjuvant formulated in 200 microliters of lyophilized liposome/ polyI:C/ hydrophobic carrier as described above. All animals were bled before injection and then again at either 4 or 5 weeks post- immunization. HAI titers in these sera were examined by the H5N1 hemagglutination inhibition assay described above.

20 By 4 or 5 weeks post-vaccination with lyophilized liposome/ polyI:C/ hydrophobic carrier formulations both the mice and rabbits generated HAI titers that indicate protection against influenza H5N1. A HAI serum titer of 40 (log 10 equal to 1.60) is typically accepted to mean an individual has a protective level of antibodies targeting a specific strain of influenza. At 5 weeks post-vaccination mice generated titers ranging 25 from 128 (log 10 of 2.11) to 512 (log 10 of 2.71). At 4 weeks post-immunization rabbits generated HAI titers ranging from 64 (log 10 equal to 1.81) up to 1024 (log 10 of 3.01). It is generally accepted that a single vaccination of rHA used at the dosages described above is incapable of inducing the high HAI titers achieved in all vaccinated subject. Titters of this magnitude, generated in two different animal models, show that the 30 lyophilized liposome/ polyI:C/ hydrophobic carrier formulations is particularly effective in generating strong antibody levels in the protective range (HAI > 20 or log value > 1.3) in all vaccinated subject in as little as 4 weeks following vaccination.

### EXAMPLE 9

Pathogen free, female CD1 mice, 6-8 weeks of age, were obtained from Charles River Laboratories (St Constant, QC, Canada) and were housed according to institutional guidelines with water and food ad libitum, under filter controlled air circulation.

5 The amyloid  $\beta$  protein fragment (1-43) was purchased from Anaspec (San Jose, CA, USA) and used as a model antigen to test the efficacy of vaccine formulations. This peptide, hereafter referred to as  $\beta$ -amyloid, has a molecular weight of approximately 4,600 daltons and is associated the formation of plaques in the brains of Alzheimer's patients.  $\beta$ -amyloid was used at 10 micrograms per 100 microliter dose.

10 The 21 amino acid peptide FNNFTVSFWLRVPKVSASHLE, hereafter referred to as F21E, was purchased from NeoMPS (San Diego, CA, USA). This tetanus toxoid peptide (amino acids 947-967) is identified as being a T-helper epitope. F21E was used as a model T-helper epitope to test the efficacy of vaccine formulations; it was used at 20 micrograms per 100 microliter dose.

15 As in Examples 1 through 6, vaccine efficacy was assessed by enzyme-linked immunosorbent assay (ELISA). The same procedures as described in Example 1 were used with changes to allow for the detection of  $\beta$ -amyloid specific antibodies. Briefly, a 96-well microtiter plate is coated with antigen ( $\beta$ -amyloid, 1 microgram/ milliliter) overnight at 4 degrees Celsius, blocked with 3% gelatin for 30 minutes, then incubated  
20 overnight at 4 degrees Celsius with serial dilutions of sera, typically starting at a dilution of 1/1000. A secondary reagent (protein G conjugated to alkaline phosphatase, EMD chemicals, Gibbstown, NJ, USA) is then added to each well at a 1/500 dilution for one hour at 37 degrees Celsius. Following a 60 minute incubation with a solution containing 1 milligram/ milliliter 4-nitrophenyl phosphate disodium salt hexahydrate (Sigma-Aldrich  
25 Chemie GmbH, Switzerland), the 405 nanometer absorbance of each well is measured using a microtiter plate reader (ASYS Hitech GmbH, Austria). Endpoint titers are calculated as described in Frey A. et al (Journal of Immunological Methods, 1998, 221:35-41). Calculated titers represent the highest dilution at which a statistically significant increase in absorbance is observed in serum samples from immunized mice versus  
30 serum samples from naïve, non-immunized control mice. Titers are presented as log10 values of the endpoint dilution.

To formulate vaccine described herein, a 10:1 w:w homogenous mixture of S100 lecithin and cholesterol (Lipoid GmbH, Germany) was hydrated in the presence of a

β-amyloid and F21E solution in phosphate buffered saline (pH 7.4) to form liposomes with encapsulated antigen and T-helper. In brief, 100 micrograms of β-amyloid and 200 micrograms of F21E were first suspended in 300 microliters of phosphate buffered saline (pH 7.4) then added to 132 milligrams of the S100 lecithin/ cholesterol mixture to form approximately 450 microliters of a liposome suspension encapsulating the β-amyloid antigen and F21E T-helper. The liposome preparation was extruded by passing the material through a manual mini-extruder (Avanti, Alabaster, AL, USA) fitted with a 400 nanometer polycarbonate membrane. For every 450 microliters of liposome suspension containing β-amyloid and F21E, 2 milligrams of Imject Alum adjuvant (Pierce, Rockford, IL, USA) was added. For every 500 microliters of a liposome/ antigen/ T-helper/ adjuvant suspension, an equal volume of a mineral oil carrier (known as Montanide(TM) ISA 51, supplied by Seppic, France) was added to form a water-in-oil emulsion with the liposome suspension contained within the water phase of the emulsion and the oil forming a continuous hydrophobic phase. Each vaccine dose consisted of 100 microliters of the above-described emulsion containing liposomes, β-amyloid antigen, F21E T-helper, alum adjuvant, and the mineral oil carrier. This vaccine formulation will be referred to as liposome/ alum/ hydrophobic carrier.

To formulate the vaccine corresponding to the invention, the same procedures described above were used with the following exception: following the formation of liposomes encapsulating β-amyloid and F21E, and after extruding the liposome suspension through a 400 nanometer polycarbonate membrane, 100 micrograms of RNA-based polyI:C adjuvant (Pierce, Rockford, IL, USA) were added to every 450 microliters of liposomes. For every 500 microliters of a liposome/ antigen/ T-helper/ adjuvant suspension, an equal volume of a mineral oil carrier (Montanide(TM) ISA 51, Seppic, France) was added to form a water-in-oil emulsion with the liposome suspension contained in the water phase of the emulsion and the oil forming the continuous phase. Each vaccine dose consisted of 100 microliters of the above described emulsion containing liposomes, β-amyloid antigen, F21E T-helper, polyI:C adjuvant, and the mineral oil carrier. This particular formulation will be referred to as liposome/ polyI:C/ hydrophobic carrier.

The efficacy of the two emulsion formulations described above was compared. Two groups of mice (9 mice per group) were injected intraperitoneally with liposome vaccine formulations as follows: Group 2 mice were vaccinated with Vaccine G comprising 10 micrograms of β-amyloid and 20 micrograms of F21E formulated in 100 microliters of liposome/ alum/ hydrophobic carrier as described above. Each vaccine

dose effectively contained 200 micrograms of alum. Group 1 mice were vaccinated with Vaccine H comprising 10 micrograms of  $\beta$ -amyloid antigen and 20 micrograms F21E formulated in 100 microliters of liposome/ polyI:C/ hydrophobic carrier as described above. Each vaccine dose effectively contained 10 micrograms of polyI:C. Serum 5 samples were collected from all mice at 4, 8 and 12 weeks post-immunization. Antibody titers in these sera were examined by ELISA as described above.

Group 2 mice, vaccinated with a single dose of a liposome/ alum/ hydrophobic carrier formulation, generated a detectable antigen-specific antibody response as was expected. The endpoint titers at 4 and 8 weeks post-vaccination were 10 up to 1/32,000 (log10 value of 4.51) and at 12 weeks they were up to 1/64,000 (log 10 of 4.81). The presence of such antibody responses confirms that a genuine immune response was generated as a result of vaccination. Group 1 mice that were injected once with the formulation corresponding to the invention were able to generate an enhanced immune response with endpoint titers reaching up to 1/256,000 (log10 value of 5.41) at 4, 15 8 and 12 weeks post-vaccination. The titers generated with the invention were 7 times higher on average at every time point relative to titers generated by the control formulation containing the generic adjuvant alum. The increase in titers achieved with the invention was statistically significant (P value <0.01 at weeks 8 and 12 post-vaccination). These results confirm through the use of a different antigen model that liposome/ 20 hydrophobic carrier formulations containing a polyI:C adjuvant are capable of generating a significantly enhanced *in vivo* immune response compared to a liposome/ alum/ hydrophobic vaccination.

#### EXAMPLE 10

Pathogen free, female CD1 mice, 6-8 weeks of age, were obtained from 25 Charles River Laboratories (St Constant, QC, Canada) and were housed according to institutional guidelines with water and food ad libitum, under filter controlled air circulation.

The H5N1 recombinant hemagglutinin protein was purchased from Protein Sciences (Meridien, CT, USA). This recombinant protein has an approximate molecular weight of 72,000 daltons and corresponds to the hemagglutinin glycoprotein, an antigenic 30 protein present on the surface of the H5N1 influenza virus. This recombinant protein, hereafter designated rHA, was used as a model antigen to test the efficacy of vaccine formulations. rHA was used at 0.5 micrograms per 50 microliter dose.

Both the humoral (TH1) and cellular (TH2) immune responses were assessed by enzyme-linked immunosorbent assay (ELISA), a method that allows the detection of antigen-specific antibody levels in the serum of immunized animals. Briefly, a 96-well microtiter plate is coated with antigen (rHA, 1 microgram/ milliliter) overnight at 4 degrees Celsius, blocked with 3% gelatin for 30 minutes, then incubated overnight at 4 degrees Celsius with serial dilutions of sera, typically starting at a dilution of 1/2000. A secondary antibody, anti-IgG, is then added to each well at a 1/2000 dilution for one hour at 37 degrees Celsius. For the detection of IgG2A antibodies, indicative of a TH1 cellular response, goat anti-mouse IgG2A (SouthernBiotech, Birmingham, AL, USA) was used.

For the detection of a TH2 humoral response a goat anti-mouse IgG1 (SouthernBiotech, Birmingham, AL, USA) secondary reagent was used. Following a 60 minute incubation with a solution containing 1 milligram/ milliliter 4-nitrophenyl phosphate disodium salt hexahydrate (Sigma-Aldrich Chemie GmbH, Switzerland), the 405 nanometer absorbance of each well is measured using a microtiter plate reader (ASYS Hitech GmbH, Austria).

Endpoint titers are calculated as described in Frey A. et al (Journal of Immunological Methods, 1998, 221:35-41). Calculated titers represent the highest dilution at which a statistically significant increase in absorbance is observed in serum samples from immunized mice versus serum samples from naïve, non-immunized control mice. Titers are presented as log10 values of the endpoint dilution.

To formulate vaccines corresponding to the invention, a 10:1 w:w homogenous mixture of S100 lecithin and cholesterol (Lipoid GmbH, Germany) was hydrated in the presence of a rHA solution in phosphate buffer to form liposomes with encapsulated rHA and followed by the addition of RNA-based polyI:C (Pierce, Rockford, IL, USA) as described in Example 8. In brief, 10 micrograms of rHA were first suspended in 650 microliters of 50 millimolar phosphate buffer (pH 7.0) then added to 132 milligrams of the S100 lecithin/ cholesterol mixture to form approximately 800 microliters of a liposome suspension encapsulating the rHA antigen. The liposome preparation was then extruded by passing the material through a manual mini-extruder (Avanti, Alabaster, AL, USA) fitted with a 200 nanometer polycarbonate membrane. PolyI:C adjuvant in 50 millimolar phosphate buffer (pH7.0) was added to sized liposomes to dilute the preparation to 1 milliliter. For the "high dose" polyI:C formulation, 240 micrograms of polyI:C in phosphate buffer was added and for the "low dose" polyI:C formulation 50 micrograms of polyI:C were added. Liposomes were then lyophilized using the Virtis Advantage freeze dryer (SP Industries, Warminster, PA, USA). The lyophilized material was reconstituted with a mineral oil carrier (Montanide(TM) ISA 51, supplied by Seppic,

France) up to the original 1 milliliter volume of solubilized liposomes. Each vaccine dose consisted of 50 microliters of the above described formulation combining liposomes, rHA antigen, polyI:C adjuvant, and the mineral oil carrier. These vaccine formulations will be referred to as lyophilized liposome/ polyI:C (high)/ hydrophobic carrier and lyophilized liposome/ polyI:C (low)/hydrophobic carrier.

5 The TH1 and TH2 responses generated, as a result of vaccination with the lyophilized liposome formulations containing polyI:C adjuvant, were compared. Two groups of mice (N=5 per groups) were injected intramuscularly with 50 microliters of either Vaccine E comprising 0.5 micrograms rHA and 12 micrograms polyI:C formulated as 10 lyophilized liposomes/ polyI:C (high)/ hydrophobic carrier (Group 1) or Vaccine I comprising 0.5 micrograms rHA and 2.5 micrograms polyI:C formulated as lyophilized liposomes/ polyI:C (low)/ hydrophobic carrier (Group 2). Serum samples were collected at 5 weeks post-immunization and IgG1 and IgG2A antibody titers examined as described above.

15 Group 1 mice generated IgG1 titres up to 2,048,000 (log 10 value of 6.31) at 5 weeks post-immunization which is comparable to the humoral response results of the similar lyophilized liposomes/ polyI:C/ hydrophobic carrier formulation used in Example 3. The IgG2A titers, indicative of a cellular response, were up to 4,096,000 (log 10 equal to 6.61) at 5 weeks post-vaccination. Group 2 mice, vaccinated with a lower dose of polyI:C, 20 generated at 5 weeks post-vaccination IgG1 titers up to 4,096,000 (log 10 of 6.61) and IgG2A titers also up to 4,096,000. Results show that polyI:C adjuvant formulated at various concentrations in a lyophilized liposome/ hydrophobic carrier formulation is able to generate both humoral (TH2) and cellular (TH1) immune responses. These results suggest that the formulations described above are capable of generating cellular and 25 humoral immune responses in vaccinated subjects.

### Example 11

Pathogen free, female C57BL6 mice, 4-6 weeks of age, were obtained from Charles River Laboratories (St Constant, QC, Canada) and were housed according to institutional guidelines with water and food ad libitum, under filter controlled air 30 circulation.

The antigen used in vaccine formulations was a fusion protein consisting of the H2-Db immunodominant epitope of HPV16 E7 (49-57; RAHYNIVTF) fused to the universal T helper epitope PADRE. This antigen, hereafter referred to as FP, was

synthesized by Anaspec Inc. (San Jose, CA). The adjuvant was a RNA-based poly inosine-cytosine RNA molecule provided by Sigma-Genosys (St. Louis, MO).

The efficacy of the invention comprising liposomes, an RNA-based poly I:C molecule, and a hydrophobic carrier was tested *in vivo* using a C3 tumor challenge model.

5 C3 cells contain the human papilloma virus 16 (HPV16) genome and as a result, present on their surface the HPV16 E7 epitope (amino acids 49-57; RAHYNIVTF) which can be targeted by vaccination. C3 cells grow into measurable solid tumors when injected subcutaneously. Three groups of mice (n=8 per group) were implanted subcutaneously in the flank with the HPV16 E7 expressing tumor cell line C3 ( $5 \times 10^5$  cells/ mouse) on

10 day 0. On day 8, mice in Groups 1 and 2 were vaccinated subcutaneously in the opposing flank with 100 microliters of vaccine. Group 3 mice received PBS only and served as the tumor growth control. Tumor volume was measured once a week using callipers to record the shortest diameter and longest diameter for 5 weeks post implantation. Tumor volume was calculated using the following formula: longest

15 measurement  $\times$  (shortest measurement) $^2$  divided by 2.

The control vaccine (conventional emulsion) used to immunize Group 1 was formulated by mixing 300 micrograms of FP antigen and 3 milligrams of PolyI:C adjuvant in 1 millilitre of PBS. For every 500 microliters of antigen/ adjuvant suspension, an equal volume of a mineral oil carrier (Montanide(TM) ISA 51, supplied by Seppic, 20 France) was added to form a water-in-oil emulsion. Each vaccine dose consisted of 100 microliters of the described emulsion containing FP antigen (15 micrograms) and polyI:C adjuvant (150 micrograms) and the mineral oil carrier. This vaccine formulation will be referred to as polyI:C/ hydrophobic carrier.

To formulate vaccine (Vaccine K) corresponding to the invention for

25 Group 2, the same procedures as described in Example 1 were used. Briefly, 150 micrograms of FP antigen was mixed with a DOPC lecithin/ cholesterol mixture (10:1, w:w; Lipoid GmbH, Germany) dissolved in tert-butanol and lyophilized. Liposomes were formulated by adding 1 millilitre of 50 millimolar phosphate buffer (pH 7.0) containing 1.5 milligrams of polyI:C. The liposome preparation was extruded by passing the material

30 through a manual mini-extruder (Avanti, Alabaster, AL, USA) fitted with a 200 nanometer polycarbonate membrane. Liposome size was confirmed at 200 nanometers using a Malvern Particle Size Analyzer (Worcestershire, United Kingdom). For every 500 microliters of a liposome/ antigen/ adjuvant suspension, an equal volume of a mineral oil carrier (Montanide(TM) ISA 51, supplied by Seppic, France) was added to form a water-

in-oil emulsion with the liposome suspension contained within the water phase of the emulsion and the oil forming a continuous hydrophobic phase. Each vaccine dose consisted of 100 microliters of the described emulsion containing liposomes (13.2 milligrams of DOPC/cholesterol), FP antigen (15 micrograms), polyI:C adjuvant (150 micrograms), and the mineral oil carrier. This vaccine formulation will be referred to as 5 liposome/ polyI:C/ hydrophobic carrier.

The results of this experiment are shown in **Figure 11**. Group 1 mice had partial protection from tumor growth and started to develop measurable tumors by week 4 post implantation. The mice in Group 2, vaccinated with the invention, developed 10 significantly smaller tumors that were only detectable by week 5 ( $p<0.1$ ). The mice in the control group developed tumors with expected kinetics, starting at week 3 post implantation.

These results indicate that tumor-specific antigens formulated in the liposome/ polyI:C/ hydrophobic carrier formulation was more effective at therapeutically 15 treating an established tumor in mice than when formulated with polyI:C/ hydrophobic carrier. The optimal therapeutic effect could only be achieved when liposomes were present in the formulation, clearly indicating that liposomes are a critical component of the invention.

### Example 12

20 Pathogen free, female C57BL6 mice, 4-6 weeks of age, were obtained from Charles River Laboratories (St Constant, QC, Canada) and were housed according to institutional guidelines with water and food ad libitum, under filter controlled air circulation.

As in Example 11, the antigen used in vaccine formulations was a fusion 25 protein consisting of the H2-Db immunodominant epitope of HPV16 E7 (49-57; RAHYNIVTF) fused to the universal T helper epitope PADRE. This antigen, hereafter referred to as FP, was synthesized by Anaspec Inc. (San Jose, CA). The adjuvant was a DNA-based poly inosine-cytosine DNA molecule consisting of 13 (IC) repeats and synthesized by Operon MWG (Huntsville, AL, USA).

30 The efficacy of the invention comprising liposomes, a DNA-based polyI:C and a hydrophobic carrier was tested *in vivo* using the C3 tumor challenge model described earlier. Four groups of mice (n=8 per group) were implanted subcutaneously in the flank

with the HPV16 E7 expressing tumor cell line C3 ( $5 \times 10^5$  cells/ mouse) on day 0. On day 5, mice in Groups 1 to 3 were vaccinated subcutaneously in the opposing flank with vaccine. Group 4 mice received PBS only and served as the tumor growth control. Tumor volume was measured once a week using callipers to record the shortest diameter 5 and longest diameter for 5 weeks post implantation. Tumor volume was calculated using the following formula: longest measurement  $\times$  (shortest measurement $^2$  divided by 2.

Mice in Group 1 were vaccinated with Vaccine L comprising a liposome/ antigen/ poly IC / hydrophobic carrier. The vaccine was formulated as in Example 11. Each dose volume was 100 microliters and contained liposomes, FP (10 micrograms), poly IC (20 10 micrograms) and was emulsified with the mineral oil carrier. Mice in Group 2 were vaccinated with Vaccine M comprising a lyophilized liposome/ antigen/ poly IC/ hydrophobic carrier. Briefly, a 10:1 (w:w) homogenous mixture of DOPC lecithin and cholesterol (Lipoid GmbH, Germany) was hydrated in the presence of 200 micrograms of FP and 400 micrograms of poly IC in 0.5% PEG/water to form 1 milliliter of liposomes with 15 encapsulated antigen and adjuvant. The liposome preparation was extruded by passing the material 20 times through a manual extruder (Avanti, Alabaster, AL, USA) fitted with two 400 nanometer polycarbonate membranes. Liposome size was confirmed at 200 nanometers using a Malvern Particle Size Analyzer (Worchestershire, United Kingdom). Liposomes containing antigen and adjuvant were lyophilized using the Virtis Advantage 20 freeze dryer (SP Industries, Warminster, PA, USA). The lyophilized material was reconstituted in oil up to the original volume of solubilized liposomes with a mineral oil carrier (Montanide(TM) ISA 51, Seppic, France). Each dose volume was 50 microliters and contained liposomes (6.6 mg of DOPC/cholesterol), FP (10 micrograms), polyI:C (20 micrograms) and the mineral oil carrier. Mice in Group 3 were vaccinated with a 25 lyophilized liposome/ antigen/ hydrophobic carrier formulated as for Group 2, except without the poly IC adjuvant (adjuvant control).

Results of this experiment are shown in **Figure 12**. Group 1 and group 2 mice did not develop measurable tumors throughout the length of the study. Mice in Group 3, which were vaccinated with the lyophilized liposome formulation with FP but no 30 adjuvant, started to develop tumors at week 3 post implantation. Mice in the PBS control group developed tumors with expected kinetics, starting at week 3 post implantation.

These results indicate that vaccine formulations of the present invention require a poly IC adjuvant to be efficacious in a tumor challenge model. In this example, a DNA-based polyI:C adjuvant formulated in a liposome/ hydrophobic carrier or in a

lyophilized liposome/ hydrophobic carrier formulation generated an effective immune response with therapeutic effect with as little as one immunization.

### Example 13

Pathogen free, female BALB/c mice, 6-8 weeks of age, were obtained from 5 Charles River Laboratories (St Constant, QC, Canada) and were housed according to institutional guidelines with water and food ad libitum, under filter controlled air circulation.

As in previous examples, H5N1 recombinant hemagglutinin protein, corresponding to the hemagglutinin glycoprotein on the surface of the H5N1 influenza virus, was purchased from Protein Sciences (Meridien, CT, USA). This recombinant 10 protein, hereafter designated rHA, was used as a model antigen to test the efficacy of vaccine formulations. rHA was used at 1.5 micrograms per 50 microliter dose.

Vaccine efficacy was assessed by immunofluorescence staining of memory CD8 cells, similar to the method described in Example 7. Syngenic splenocytes from BALB/c mice were activated for 48 hours at 37 degrees Celsius with 10 micrograms/ 15 milliliter of lipopolysaccharide and the resulting blasts were treated with 50 micrograms/ milliliter mitomycin C for 20 minutes at room temperature. Following repeated washes, the activated blast cells were used as antigen presenting stimulator cells for expanding flu-specific CD8 memory cells from vaccinated mice. Spleen cells from naïve or immunized mice were cultured with blast cells at a ratio of 5:1 and cultures were 20 stimulated with rHA at 0.1 micrograms/ milliliter for 6 days at 37 degrees Celsius, 5 percent carbon dioxide. Harvested cells were used for immunofluorescence staining with anti-CD8-fluorescein isothiocyanate (FITC) (eBioscience, San Diego, CA, USA) antibodies and phycoerythrin (PE)-conjugated Pro5 Flu-pentamer reagent (H2-Kd, IYSTVASSL, Proimmune, Oxford, UK). Anti-CD19-allophycocyanin (APC) (eBioscience) 25 was also used to exclude any non-specific binding of pentamer to B cells. Stained cells were collected on a FACSCalibur flow-cytometer (BD Bioscience, Mississauga, ON, Canada) and data analysis was done using WinList 6.0 software (Verity Software House, Topsham, ME, USA). Results were gated based on forward and side scatter, and antigen-specific CD8 T cells were defined as pentamer positive, CD8 $\beta$  positive and CD19 30 negative. Statistical analysis was performed using Students' T-test.

To formulate the vaccine corresponding to the invention, the same procedures as described in Examples 6 and 7 were used. In summary, a 10:1 (w:w) homogeneous mixture of S100 lecithin and cholesterol (Lipoid GmbH, Germany) was

hydrated in the presence of rHA in phosphate buffer (pH 7.0), to form liposomes encapsulating rHA, and followed by the addition of RNA-based polyI:C (Pierce, Rockford, IL, USA). The liposome suspension was extruded through a semi-automatic extruder (Avestin, Ottawa, ON, Canada) and the sized liposomes lyophilized (Virtis Advantage 5 freeze dryer, SP Industries, Warminster, PA, USA) and reconstituted in a mineral oil carrier (Montanide ISA 51(TM), SEPPIC, France). Each vaccine dose consisted of 50 microliters of the above described formulation containing liposomes, rHA antigen, polyI:C adjuvant, and the mineral oil carrier. This vaccine formulation will be referred to as lyophilized liposome/ polyI:C/ hydrophobic carrier.

10 The efficacy of the lyophilized liposome formulation described above was compared to the efficacy of a control vaccine consisting of 1.5 micrograms of rHA and 100 micrograms of Imject Alum adjuvant (Pierce, Rockford, IL, USA) in 50 microliters of 50 millimolar phosphate buffer (pH 7.0). Group 1 mice (N = 5) were injected intramuscularly, once (no boosting), with 1.5 micrograms of rHA antigen and 12.5 micrograms of polyI:C 15 adjuvant formulated in 50 microliters of lyophilized liposome/ polyI:C/ hydrophobic carrier as described above. This vaccine corresponds to the same vaccine used in Examples 6 and 7 (vaccine D, the invention). Group 2 mice (N = 5) were vaccinated twice (day 0 and day 28) with a control vaccine consisting of 1.5 micrograms of rHA and 100 micrograms of alum adjuvant suspended in 50 millimolar phosphate buffer. Twenty-one weeks post- 20 vaccination, animals were euthanized by carbon dioxide induced asphyxiation, the spleens were collected and individual single cell suspensions prepared using standard procedures. The presence of flu-specific CD8 memory T cells was then assessed using the flu pentamer immunofluorescence staining described above.

25 Mice vaccinated with the control alum-based formulation generated a small population of antigen-specific CD8 memory T cells, mean population size of 0.02 percent and considered background (standard deviation 0.02 percent). Mice vaccinated with the lyophilized liposome/ polyI:C/ hydrophobic carrier formulation corresponding to the invention on the other generated a significantly higher population (P < 0.02) of antigen-specific CD8 memory T cells, mean population size of 0.51 percent (standard deviation 30 0.10 percent). These results are significant as they demonstrate that single dose lyophilized liposome/ hydrophobic carrier formulations containing polyI:C adjuvant generate a large, long-lasting, antigen-specific CD8 memory T cell population whereas an aqueous/ alum control vaccine could not generate any significant and lasting cellular response even after two immunizations.

## REFERENCES

Yoneyama M, Kikuchi M, Natsukawa T, Shinobu N, Imaizumi T, Miyagishi M, Taira K, Akira S, Fujita T. 2004. The RNA helicase RIG-I has an essential function in double-stranded RNA-induced innate antiviral responses. *Nat Immunol* 5(7):730-7.

5 Dong LW, Kong XN, Yan HX, Yu LX, Chen L, Yang W, Liu Q, Huang DD, Wu MC, Wang HY. 2008. Signal regulatory protein alpha negatively regulates both TLR3 and cytoplasmic pathways in type I interferon induction. *Mol Immunol* 45(11):3025-35. Epub 2008 May 8.

Trumpfheller C, Caskey M, Nchinda G, Longhi MP, Mizenina O, Huang Y, Schlesinger SJ, 10 Colonna M, Steinman RM. 2008. The microbial mimic poly IC induces durable and protective CD4+ T cell immunity together with a dendritic cell targeted vaccine. *Proc Natl Acad Sci U S A* 2008 Feb 19;105(7):2574-9.

Alexopoulou L, Holt AC, Medzhitov R, Flavell RA. 2001. Recognition of double-stranded RNA and activation of NF- $\kappa$ B by Toll-like receptor 3. *Nature* 413(6857):732-8.

15 Chirigos MA, Schlick E, Ruffmann R, Budzynski W, Sinibaldi P, Gruys E. 1985. *J Biol Response Mod* 4(6):621-7. Pharmacokinetic and therapeutic activity of polyinosinic-polycytidylic acid stabilized with poly-L-lysine in carboxymethylcellulose [poly(I,C)-LC].

Gowen BB, Wong MH, Jung KH, Sanders AB, Mitchell WM, Alexopoulou L, Flavell RA, Sidwell RW. 2007. TLR3 is essential for the induction of protective immunity against 20 Punta Toro Virus infection by the double-stranded RNA (dsRNA), poly(I:C12U), but not Poly(I:C): differential recognition of synthetic dsRNA molecules. *J Immunol* 178(8):5200-8.

Padalko E, Nuyens D, De Palma A, Verbeken E, Aerts JL, De Clercq E, Carmeliet P, Neyts J. 2004. The interferon inducer ampligen [poly(I)-poly(C12U)] markedly protects mice against coxsackie B3 virus-induced myocarditis. *Antimicrob Agents Chemother* 25 48(1):267-74.

Nordlund JJ, Wolff SM, Levy HB. 1970. Inhibition of biologic activity of poly I: poly C by human plasma. *Proc Soc Exp Biol Med* 133(2):439-44.

Agger EM, Rosenkrands I, Olsen AW, Hatch G, Williams A, Kritsch C, Lingnau K, von Gabain A, Andersen CS, Korsholm KS, Andersen P. 2006. Protective immunity to

tuberculosis with Ag85B-ESAT-6 in a synthetic cationic adjuvant system IC31. *Vaccine* 24(26):5452-60.

Schellack C, Prinz K, Egyed A, Fritz JH, Wittmann B, Ginzler M, Swatosch G, Zauner W, Kast C, Akira S, von Gabain A, Buschle M, Lingnau K. 2006. IC31, a novel adjuvant 5 signaling via TLR9, induces potent cellular and humoral immune responses. *Vaccine* 24(26):5461-72.

Llopiz D, Dotor J, Zabaleta A, Lasarte JJ, Prieto J, Borrás-Cuesta F, Sarobe P. 2008. Combined immunization with adjuvant molecules poly(I:C) and anti-CD40 plus a tumor antigen has potent prophylactic and therapeutic antitumor effects. *Cancer Immunol 10 Immunother* 57(1):19-29.

Riedl K, Riedl R, von Gabain A, Nagy E, Lingnau K. 2008. The novel adjuvant IC31((R)) strongly improves influenza vaccine-specific cellular and humoral immune responses in young adult and aged mice. *Vaccine* 2008 May 5 epub.

Levy HB. 1985. *J Biol Response Mod* 4(5):475-80. Historical overview of the use of 15 polynucleotides in cancer.

Ichinohe T, Tamura S, Kawaguchi A, Ninomiya A, Imai M, Itamura S, Odagiri T, Tashiro M, Takahashi H, Sawa H, Mitchell WM, Strayer DR, Carter WA, Chiba J, Kurata T, Sata T, Hasegawa H. 2007. Cross-protection against H5N1 influenza virus infection is afforded by intranasal inoculation with seasonal trivalent inactivated influenza vaccine. *J Infect Dis* 20 196(9):1313-20.

Sloat BR, Shaker DS, Le UM, Cui Z. 2008. Nasal immunization with the mixture of PA63, LF, and a PGA conjugate induced strong antibody responses against all three antigens. *FEMS Immunol Med Microbiol* 52(2):169-79.

Salem ML, El-Naggar SA, Kadima A, Gillanders WE, Cole DJ. 2006. The adjuvant effects 25 of the toll-like receptor 3 ligand polyinosinic-cytidylic acid poly (I:C) on antigen-specific CD8+ T cell responses are partially dependent on NK cells with the induction of a beneficial cytokine milieu. *Vaccine* 24(24):5119-32.

Kamath AT, Valenti MP, Rochat AF, Agger EM, Lingnau K, von Gabain A, Andersen P, Lambert PH, Siegrist CA. 2008. Protective anti-mycobacterial T cell responses through 30 exquisite *in vivo* activation of vaccine-targeted dendritic cells. *Eur J Immunol.* 38(5):1247-56.

Cui Z, Qiu F. 2006. Synthetic double-stranded RNA poly(I:C) as a potent peptide vaccine adjuvant: therapeutic activity against human cervical cancer in a rodent model. *Cancer Immunol Immunother* 55(10):1267-79.

Salem ML, Kadima AN, Cole DJ, Gillanders WE. 2005. Defining the antigen-specific T-cell response to vaccination and poly(I:C)/TLR3 signaling: evidence of enhanced primary and memory CD8 T-cell responses and antitumor immunity. *J Immunother*. 28(3):220-8.

Fujimura T, Nakagawa S, Ohtani T, Ito Y, Aiba S. 2006. Inhibitory effect of the polyinosinic-polycytidylic acid/cationic liposome on the progression of murine B16F10 melanoma. *Eur J Immunol* 36(12):3371-80.

10 Krown SE, Kerr D, Stewart WE 2nd, Field AK, Oettgen HF. 1985. Phase I trials of poly(I,C) complexes in advanced cancer. *J Biol Response Mod* 1985 Dec;4(6):640-9.

Zhu X, Nishimura F, Sasaki K, Fujita M, Dusak JE, Eguchi J, Fellows-Mayle W, Storkus WJ, Walker PR, Salazar AM, Okada H. 2007. Toll like receptor-3 ligand poly-ICLC promotes the efficacy of peripheral vaccinations with tumor antigen-derived peptide 15 epitopes in murine CNS tumor models. *J Transl Med*. 12:10.

de Clercq E, Torrence PF, Stollar BD, Hobbs J, Fukui T, Kakiuchi N, Ikehara M. 1978. Interferon induction by a 2'-modified double-helical RNA, poly(2'-azido-2'-deoxyinosinic acid) . polycytidylic acid. *Eur J Biochem*. 88(2):341-9.

Bobst AM, Langemeier PW, Torrence PF, De Clercq E. 1981. Interferon induction by 20 poly(inosinic acid).poly(cytidylic acid) segmented by spin-labels. *Biochemistry* 20(16):4798-803.

De Clercq E, Hattori M, Ikehara M. 1975. Antiviral activity of polynucleotides: copolymers of inosinic acid and N2-dimethylguanylic of 2-methylthioinosinic acid. *Nucleic Acids Res* 1975 2(1):121-9.

25 Guschlbauer W, Blandin M, Drocourt JL, Thang MN. 1977. Poly-2'-deoxy-2'-fluorocytidylic acid: enzymatic synthesis, spectroscopic characterization and interaction with poly-inosinic acid. *Nucleic Acids Res* 4(6):1933-43.

Fukui T, Kakiuchi N, Ikehara M. Polynucleotides. 1977. XLV Synthesis and properties of poly(2'-azido-2'-deoxyinosinic acid). *Nucleic Acids Res*. 4(8):2629-39.

Johnston MI, Stollar BD, Torrence PF, Witkop B. 1975. Structural features of double-stranded polyribonucleotides required for immunological specificity and interferon induction. *Proc Natl Acad Sci U S A.* 72(11):4564-8.

Kende M, Lupton HW, Rill WL, Gibbs P, Levy HB, Canonico PG. 1987. Ranking of prophylactic efficacy of poly(ICLC) against Rift Valley fever virus infection in mice by incremental relative risk of death. *Antimicrob Agents Chemother.* 31(8):1194-8.

Poast J, Seidel HM, Hendricks MD, Haslam JA, Levy HB, Baron S. 2002. Poly I:CLC induction of the interferon system in mice: an initial study of four detection methods. *J Interferon Cytokine Res* 22(10):1035-40.

10 Sarma PS, Shiu G, Neubauer RH, Baron S, Huebner RJ. 1969. *Proc Natl Acad Sci U S A* 62(4):1046-51. Virus-induced sarcoma of mice: inhibition by a synthetic polyribonucleotide complex.

Stephen EL, Sammons ML, Pannier WL, Baron S, Spertzel RO, Levy HB. 1977. Effect of a nuclease-resistant derivative of polyriboinosinic-polyribocytidyl acid complex on yellow 15 fever in rhesus monkeys (*Macaca mulatta*). *J Infect Dis* 136(1):122-6.

Levy HB, Lvovsky E. 1978. Topical treatment of vaccinia virus infection with an interferon inducer in rabbits. *J Infect Dis.* 137(1):78-81.

Durie BG, Levy HB, Voakes J, Jett JR, Levine AS. 1985. Poly(I,C)-LC as an interferon inducer in refractory multiple myeloma. *J Biol Response Mod.* 4(5):518-24.

20 Salazar AM, Levy HB, Ondra S, Kende M, Scherokman B, Brown D, Mena H, Martin N, Schwab K, Donovan D, Dougherty D, Pulliam M, Ippolito M, Graves M, Brown H, Ommaya A. 1996. Long-term treatment of malignant gliomas with intramuscularly administered polyinosinic-polycytidyl acid stabilized with polylysine and carboxymethylcellulose: an open pilot study. *Neurosurgery* 38(6):1096-103; discussion 25 1103-4.

Theriault RL, Hortobagyi GN, Buzdar AU, Levy HB, Hersh EM. 1986. Evaluation of polyinosinic-polycytidyl and poly-L-lysine in metastatic breast cancer. *Cancer Treat Rep.* 70(11):1341-2.

Nakamura O, Shitara N, Matsutani M, Takakura K, Machida H. 1982. Phase I-II trials of 30 poly(ICLC) in malignant brain tumor patients. *J Interferon Res* 2(1):1-4.

Bever CT Jr, Salazar AM, Neely E, Ferraraccio BE, Rose JW, McFarland HF, Levy HB, McFarlin DE. 1986. Preliminary trial of poly ICLC in chronic progressive multiple sclerosis. *Neurology* 36(4):494-8.

Talmadge JE, Adams J, Phillips H, Collins M, Lenz B, Schneider M, Chirigos M. 1985.

5 Immunotherapeutic potential in murine tumor models of polyinosinic-polycytidylc acid and poly-L-lysine solubilized by carboxymethylcellulose. *Cancer Res* 45(3):1066-72.

Droller MJ. 1987. Immunotherapy of metastatic renal cell carcinoma with polyinosinic-polycytidylc acid. *J Urol.* 137(2):202-6.

Awasthi A, Mehrotra S, Bhakuni V, Dutta GP, Levy HB, Maheshwari RK. 1997. Poly ICLC 10 enhances the antimalarial activity of chloroquine against multidrug-resistant *Plasmodium yoelii nigeriensis* in mice. *J Interferon Cytokine Res.* 17(7):419-23.

Puri SK, Dutta GP, Levy HB, Maheshwari RK. 1996. Poly ICLC inhibits *Plasmodium cynomolgi B* malaria infection in rhesus monkeys. *J Interferon Cytokine Res.* 16(1):49-52.

Houston WE, Crabbs CL, Stephen EL, Levy HB. 1976. Modified polyriboinosinic-15 polyribocytidylc acid, an immunological adjuvant. *Infect Immun* 14(1):318-9.

Stephen EL, Hilmas DE, Mangiafico JA, Levy HB. 1977. Swine influenza virus vaccine: potentiation of antibody responses in rhesus monkeys. *Science* 197(4310):1289-90.

Zaks K, Jordan M, Guth A, Sellins K, Kedl R, Izzo A, Bosio C, Dow S. 2006. Efficient 20 immunization and cross-priming by vaccine adjuvants containing TLR3 or TLR9 agonists complexed to cationic liposomes. *J Immunol* 176(12):7335-45.

Hendrix CW, Margolick JB, Petty BG, Markham RB, Nerhood L, Farzadegan H, Ts'o PO, Lietman PS. 1993. Biologic effects after a single dose of poly(I):poly(C12U) in healthy volunteers. *Antimicrob Agents Chemother.* 37(3):429-35.

Greene JJ, Alderfer JL, Tazawa I, Tazawa S, Ts'o PO, O'Malley JA, Carter WA. 1978. 25 Interferon induction and its dependence on the primary and secondary structure of poly(inosinic acid).poly(cytidylc acid). *Biochemistry* 17(20):4214-20.

All publications and patent applications cited in this specification are herein incorporated by reference as if each individual publication or patent application were specifically and individually indicated to be incorporated by reference. The citation of any 30 publication is for its disclosure prior to the filing date and should not be construed as an

admission that the present invention is not entitled to antedate such publication by virtue of prior invention.

As used in this specification and the appended claims, the singular forms "a," "an," and "the" include plural reference unless the context clearly dictates otherwise.

- 5 Unless defined otherwise all technical and scientific terms used herein have the same meaning as commonly understood to one of ordinary skill in the art to which this invention belongs.

Although the foregoing invention has been described in some detail by way of illustration and example for purposes of clarity of understanding, it is readily apparent to 10 those of ordinary skill in the art in light of the teachings of this invention that certain changes and modifications may be made thereto without departing from the spirit or scope of the appended claims.

CLAIMS:

1. A composition comprising:
  - (a) an antigen;
  - (b) liposomes;
  - 5 (c) a polyI:C polynucleotide; and
  - (d) a carrier comprising a continuous phase of a hydrophobic substance.
2. The composition according to claim 1, wherein the polyI:C polynucleotide comprises RNA or DNA.
3. The composition according to claim 1, wherein the polyI:C polynucleotide 10 comprises RNA and DNA.
4. The composition according to any one of claims 1-3, wherein the polyI:C polynucleotide is a homopolymer or a heteropolymer.
5. The composition according to any one of claims 1-3, wherein the polyI:C polynucleotide comprises a homopolymeric polyI:C polynucleotide and a heteropolymeric 15 polyI:C polynucleotide.
6. A method for making a composition, said method comprising combining, in any order:
  - a) an antigen;
  - (b) liposomes;
  - 20 (c) a polyI:C polynucleotide; and
  - (d) a carrier comprising a continuous phase of a hydrophobic substance.
7. The method according to claim 6, wherein said antigen is encapsulated in said liposomes.
8. The method according to claim 6 or 7, wherein said polyI:C polynucleotide 25 is encapsulated in said liposomes.

9. The method according to claim 6 or 7, wherein said polyI:C polynucleotide is added outside said liposomes.

10. A composition prepared according to the method of any one of claims 6 to 9.

5 11. A method comprising administering the composition according to any one of claims 1 – 5 and 10 to a subject in need thereof.

12. The method according to claim 11, which is a method for inducing an antibody response and/or cell-mediated immune response to said antigen in said subject.

13. The method according to claim 11, which is a method for the treatment 10 and/or prevention of a disease caused by a bacteria, a virus, a fungus, a parasite, an allergen or a tumor cell that expresses the antigen.

14. The method according to claim 13, wherein the treatment and/or prevention comprises inducing an antibody and/or a cell mediated immune response to the antigen in the subject, wherein the subject has or is at risk of developing a viral 15 infection.

15. The method according to claim 14, wherein the viral infection is an influenza virus infection.



16. The method according to claim 13, wherein the treatment and/or prevention comprises inducing an antibody and/or a cell mediated immune response to 20 the antigen in the subject, wherein the subject has or is at risk of developing cancer.

17. The method according to claim 11, which is a method for the treatment and/or prevention of a neurodegenerative disease, wherein the neurodegenerative disease is associated with expression of the antigen.



18. The method according to claim 17, wherein the neurodegenerative disease 25 is Alzheimer's disease.

19. The method according to any one of claims 11 - 18, wherein the composition induces an immune response in the subject that is at least 1.5x higher relative to a response induced by a control composition.



20. The method according to claim 19, wherein the composition induces an immune response in the subject that is at least 5x higher relative to a response induced by a control composition.
21. The method according to any one of claims 11 - 20, wherein the composition is administered via a route that is nasal, oropharyngeal, ocular, oral, rectal, sublingual, genitourinary mucosa, intranasal, oropharyngeal, intratracheal, intrapulmonary, transdermal, transpulmonary, intraarterial, intradermal, intramuscular, intraperitoneal, intravenous, subcutaneous or submucosal.

**FIG. 1****FIG. 2**



2/7

**FIG. 3****FIG. 4**

3/7

**FIG. 5****FIG. 6**

4/7

**FIG. 7****FIG. 8**

5/7




FIG. 9







FIG. 10

6/7

**FIG. 11****FIG. 12**

7/7

**FIG. 13**

**INTERNATIONAL SEARCH REPORT**

International application No.  
PCT/CA2009/000692

**A. CLASSIFICATION OF SUBJECT MATTER**  
IPC: **A61K 39/00** (2006.01), **A61K 39/39** (2006.01), **A61K 9/127** (2006.01), **A61P 25/28** (2006.01),  
**A61P 35/00** (2006.01), **A61P 37/04** (2006.01)

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)

IPC: **A61K 39/00** (2006.01), **A61K 39/39** (2006.01), **A61K 9/127** (2006.01), **A61P 25/28** (2006.01),  
**A61P 35/00** (2006.01), **A61P 37/04** (2006.01)

According to International Patent Classification (IPC) or to both national classification and IPC

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic database(s) consulted during the international search (name of database(s) and, where practicable, search terms used)

CANADIAN PATENT DATABASE, EPOQUE, USPTO/WEST, ESPACENET, PUBMED, GOOGLE;

Keywords: vaccine, antigen, liposome, water-in-oil, hydrophobic, continuous phase, carrier, immunostimulant, adjuvant, PolyI:C, and polyinosinic:polycytidylic acid.

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	GUY, B. The perfect mix: recent progress in adjuvant research. Nat. Rev. Microbiol. July 2007, Vol.5, No.7, pages 505-517, ISSN 1740-1534. See abstract; Figures 2 and 3; Box 3; Table 1; page 509, right column, third paragraph; and page 511, left column, last paragraph.	1-21
Y	WO 2007/041832 (DAFTARIAN, P.M. et al.) 19 April 2007 (19-04-2007). See abstract; page 2, line 15 to page 3, line 5; and claims 1, 29 and 30.	1-21

Further documents are listed in the continuation of Box C.

See patent family annex.

* Special categories of cited documents :	
“A” document defining the general state of the art which is not considered to be of particular relevance	“T” later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
“B” earlier application or patent but published on or after the international filing date	“X” document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
“L” document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	“Y” document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
“O” document referring to an oral disclosure, use, exhibition or other means	“&” document member of the same patent family
“P” document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

14 August 2009 (14-08-2009)

Date of mailing of the international search report

2 September 2009 (02-09-2009)

Name and mailing address of the ISA/CA  
Canadian Intellectual Property Office  
Place du Portage I, C114 - 1st Floor, Box PCT  
50 Victoria Street  
Gatineau, Quebec K1A 0C9  
Facsimile No.: 001-819-953-2476

Authorized officer  
Qianfa Chen 819- 994-1374

**INTERNATIONAL SEARCH REPORT**International application No.  
PCT/CA2009/000692

## C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	JIN, B. et al. Induction of potent cellular immune response in mice by hepatitis C virus NS3 protein with double-stranded RNA. Immunology. September 2007, Vol.122, No.1, pages 15-27, ISSN 0019-2805. See the entire document.	1-21

**INTERNATIONAL SEARCH REPORT**International application No.  
PCT/CA2009/000692**Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of the first sheet)**

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons :

1.  Claim Nos. : 11-21

because they relate to subject matter not required to be searched by this Authority, namely :

Claims 11-21 are directed to a method for treatment of the human or animal body by surgery or therapy which the International Search Authority is not required to search under Rule 39.1 (iv) of the PCT.

Regardless, this Authority has carried out a search based on the alleged effect(s) or purpose(s)/use(s) of the product defined in claims 11-21.

2.  Claim Nos. :

because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically :

3.  Claim Nos. :

because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

**Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)**

This International Searching Authority found multiple inventions in this international application, as follows :

1.  As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.

2.  As all searchable claims could be searched without effort justifying additional fees, this Authority did not invite payment of additional fees.

3.  As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claim Nos. :

4.  No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claim Nos. :

**Remark on Protest**  The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee.

The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation.

No protest accompanied the payment of additional search fees.

**INTERNATIONAL SEARCH REPORT**  
Information on patent family members

International application No.  
PCT/CA2009/000692

Patent Document Cited in Search Report	Publication Date	Patent Family Member(s)	Publication Date
WO 2007041832A1	19-04-2007	AU 2006301891A1 CA 2523032A1 CA 2533705A1 CA 2542212A1 CA 2622464A1 CN 101282742A EP 1948225A1 EP 1948225A4 JP 2009510133T	19-04-2007 07-04-2007 13-07-2007 07-04-2007 19-04-2007 08-10-2008 30-07-2008 24-12-2008 12-03-2009